

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The association between stage 1 hypertension defined by the 2017 ACCAHA Hypertension Guideline and cardiovascular deaths: a 20-year follow-up study in rural China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035190
Article Type:	Original research
Date Submitted by the Author:	22-Oct-2019
Complete List of Authors:	Wang, Mengying; Peking University Wu, Tao; Peking University Yu, Canqing; Peking University Gao, Wenjing Lv, Jun; Peking University Wu, Yiqun Qin, Xueying TANG, Xun; Department of Epidemiology and Biostatistics Gao, Pei Zhan, Siyan; Peking University Cao, Weihua Zhao, Qingshui Huang, Shaoping Yang, Dongli LI, Li-ming; Peking University Hu, Yong-Hua; Peking University
Keywords:	Hypertension < CARDIOLOGY, Stroke < NEUROLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The association between stage 1 hypertension defined by the 2017 ACCAHA Hypertension
Guideline and cardiovascular deaths: a 20-year follow-up study in rural China

Mengying Wang¹, Tao Wu^{1*}, Canqing Yu¹, Wenjing Gao¹, Jun Lv¹, Yiqun Wu¹, Xueying
Qin¹, Xun Tang¹, Pei Gao¹, Siyan Zhan¹, Weihua Cao¹, Qingshui Zhao², Shaoping Huang²,
Dongli Yang³, Liming Li¹, Yonghua Hu¹

E-mail address for authors

Mengying Wang: 1461589478@qq.com; Tao Wu: twu@bjmu.edu.cn;

Canqing Yu: yucanqing@pku.edu.cn; Wenjing Gao: pkugwj@qq.com;

Jun Lv: lvjun@bjmu.edu.cn; Yiqun Wu: qywu118@163.com;

Xueying Qin: xueyingqin@bjmu.edu.cn; Xun Tang: tangxun@bjmu.edu.cn;

Pei Gao: pei_gao@163.com; Siyan Zhan: siyan-zhan@bjmu.edu.cn;

Weihua Cao: caoweihua60@163.com; Qingshui Zhao: zqs_67189@163.com;

Shaoping Huang: 2146733477@qq.com; Dongli Yang: 2178757723@qq.com;

Liming Li: lmlee@vip.163.com; Yonghua Hu: yhhu@bjmu.edu.cn

¹Department of Epidemiology and Biostatistics, School of Public Health, Peking University

²Fangshan District Center for Disease Control and Prevention, Beijing, China

³Fangshan District Health Commission, Beijing, China

Corresponding to:

Tao Wu, Department of Epidemiology and Biostatistics, School of Public Health, Peking
University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing, China, 100191.

E-mail: twu@bjmu.edu.cn

Abstract

Objectives: The 2017 ACC/AHA Hypertension Guideline recommended 130/80 mmHg as blood pressure (BP) target goals. However, the generalizability of this recommendation to populations at large with hypertension remains controversial. We assessed the association between BP and cardiovascular diseases (CVDs) mortality using a 20-year follow-up study in China.

Design: Prospective cohort study.

Participants: 8,189 participants were followed up for a median of 20 years in Fangshan District, Beijing, China.

Methods: The primary outcome variable was death from cardiovascular causes. The adjusted hazard ratio (HR) for CVDs mortality associated with baseline BP were calculated using Cox regression analysis.

Results: We identified 350 deaths from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs) during follow-up. Hypertension (defined by systolic BP (SBP) /diastolic BP (DBP) $\geq 140/90$ mm Hg) was significantly associated with the risk of mortality due to CVDs (HR=2.49, 95% CI=1.77-3.50) among people aged 35-59 years rather than people aged ≥ 60 . In addition, there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA (SBP/DBP of 130-139/80-89 mm Hg) and CVDs mortality when compared with SBP/DBP of $<120/80$ in neither the participants aged <60 years (HR=0.90, 95% CI=0.54-1.50) nor participants aged ≥ 60 years (HR=1.47, 95% CI=0.94-2.29).

Conclusion: The study revealed hypertension of SBP/DBP $\geq 140/90$ mm Hg was an important risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage

1
2
3
4 1 hypertension under the definition of 2017 ACC/AHA was not associated with increased risk
5
6 of CVDs mortality. This study indicated that whether adopting the new hypertension
7
8 definition needs further consideration in rural China.
9
10

11 **Keywords:** hypertension; mortality; cardiovascular diseases; cohort study
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

1. The prospective study had a relatively long follow-up time of 20 years.
2. The study examined the association between high blood pressure and the risk of mortality from CVDs, which were hard outcomes.
3. Hypertension was defined by systolic blood pressure or diastolic blood pressure at baseline while we failed to acquire blood pressure measurements during follow-up, which may underestimate the strength of the associations we observed.
4. Whether the effects of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or chronic kidney disease was not explored due to limited data.
5. The information of death was obtained from the Death Surveillance System, the participants lost to follow-up were hard to detect and may cause potential bias.

Introduction

Hypertension is the first risk factor of cardiovascular diseases (CVDs), accounted for 7.8 million deaths and 148 million disability life years lost worldwide in 2015 [1]. It has been reported that hypertension affected nearly 30% of the adult population in western countries as well as in China [2,3].

The management of high blood pressure is a public health priority with implications for the prevention of CVDs [4,5]. However, the optimal blood pressure, particularly for systolic blood pressure (SBP) treatment target is unclear worldwide. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults recommended 130/80 mmHg as blood pressure target goals [6]. However, the definition of hypertension remains $\geq 140/90$ mm Hg in the European guideline [7].

The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated intensive SBP lowering in adults without diabetes or stroke could result in significant decreases in cardiovascular events and all-cause mortality [8]. A network meta-analysis conducted by Bundy et al also suggested that a more intensive treatment target (eg, SBP of 120-124 mm Hg) showed improvement in the prevention of CVD complications and total mortality when compared with a standard SBP target (< 140 mm Hg) [9]. However, the generalizability of SPRINT findings to populations at large with hypertension remains controversial [9,10]. Sun et al found that compared with hypertensive patients with baseline SBP < 140 mmHg, intensive

1
2
3
4 SBP lowering could not improve clinical outcomes but generated more treatment-related
5
6 adverse events among those with higher baseline SBP (≥ 140 mmHg) [11]. In addition, a recent
7
8 study showed that the treatment to achieve a target SBP of 110 to 139 mm Hg did not result
9
10 in a lower rate of death than standard reduction to a target of 140 to 179 mmHg in hypertensive
11
12 patients with intracerebral hemorrhage [12]. Furthermore, a cohort study showed that the
13
14 hazard ratios (HRs) comparing stage 1 hypertension (130 to 139/80 to 89 mm Hg) to intensive
15
16 blood pressure control ($< 120/80$ mmHg) for CVDs incidence and mortality were significant
17
18 among participants aged 35 to 59 years but not in those aged ≥ 60 years among Chinese
19
20 populations [13].
21
22
23
24
25
26
27
28
29

30 Here, we aimed to assess the relative risk of CVDs mortality associated with different stages
31
32 of hypertension according to 2017 ACC/AHA using a 20-year follow-up study in China, to
33
34 further evaluate the generalizability of SPRINT findings and explore the target blood pressure
35
36 levels among Chinese populations.
37
38
39
40
41
42

43 **Methods**

44 **Study design and participants**

45
46 The participants for these analyses came from a community-based follow-up study for the
47
48 prevention and treatment of hypertension, which is being conducted in Fangshan District,
49
50 Beijing, China. From month 1996/1997 through month 1998/1999, 8,189 participants aged
51
52 35 to 97 years were enrolled. Informed consent was obtained from all participants. In addition,
53
54 the study was approved by the Institutional Review Board of Peking University Health
55
56
57
58
59
60

1
2
3
4 Science Center.
5
6
7
8

9 **Outcomes variables**

10
11 The primary outcome variable was death from CVDs. The information of death was
12 continuously obtained from the Death Surveillance System in the Center for Disease
13 Prevention and Control in Fangshan District. Date of death was ascertained from the record
14 in the system. We determined survival times from the date participants investigated in the
15 baseline survey through December 31, 2017. Participants who were alive at the end of this
16 period contributed with censored observations to the survival analyses of time to death. The
17 causes of death were coded using the International Classification of Diseases, Ninth Revision
18 (ICD-9) codes from 1997 to 2001, and International Classification of Diseases, Tenth
19 Revision (ICD-10) codes from 2002-2017. Among the 8,189 participants, we excluded 669
20 individuals with CVDs at baseline. In addition, we dropped the participants if any of the key
21 variables required in the analysis (blood pressure, height, weight, demographic variables, or
22 potential risk factors including smoking, alcohol consumption, or high salt intake) was
23 missing. Finally, a total of 7,314 participants (3,346 males and 3,968 females) were included
24 in the analysis.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Data collection**

51
52 The primary exposure variables for these analyses included age at the enrollment and the
53 blood pressure level at baseline. Data on sociodemographic characteristics, lifestyles, and
54 medical history of the participants were collected through questionnaire interview by trained
55
56
57
58
59
60

1
2
3
4 staff members.
5
6
7
8

9 Participants were defined as never smokers, former smokers, and current smokers.
10
11 Information on alcohol consumption was obtained through asking the participants to describe
12 their drinking status: never, light (less than 2 drinks a day), or heavy (≥ 2 drinks a day). Further,
13
14 the salt intake of the participants was assessed according to the question of what kind of taste
15 they liked (salty taste, moderate, or light taste).
16
17
18
19
20
21
22
23
24

25 Physical measurements included height, weight, and blood pressure. Blood pressure levels were
26 measured 3 times using a mercury sphygmomanometer by trained investigators. The mean of
27 the 3 recorded measurements were included in the analysis. Hypertension was defined as SBP
28 ≥ 140 mm Hg, systolic blood pressure (DBP) ≥ 90 mm Hg, self-reported antihypertensive
29 medication in the past 2 weeks, or self-reported history of hypertension [3].
30
31
32
33
34
35
36
37
38
39

40 **Statistical analysis**

41
42 Student's t-test and Chi-square test were used to test the differences between different baseline
43 hypertensive history groups for continuous variables and categorical variables, respectively.
44
45
46
47
48
49

50 Person-years for each participant were calculated as the duration from the survey date at
51 baseline through death date or date of lost to follow-up, whichever came first. The Cox
52 proportional hazards regression model for CVDs death included baseline blood pressure level,
53 age, sex, education level, body mass index, smoking status, alcohol use, dietary salt intake,
54
55
56
57
58
59
60

1
2
3
4 antihypertensive medications, and family history of hypertension. Participants were classified
5
6 as two groups according to baseline hypertensive status, and non-hypertension (<140/90
7
8 mmHg) was treated as reference. To test for possible interactions between age and
9
10 hypertension, we categorized age with cutoffs of 60 years and hypertension as binary
11
12 variables, and setting variable cross-product terms of hypertension (yes/no) with age (<60
13
14 and ≥ 60 years) in the model. Reference groups were SBP/DBP of less than 140/90 mm Hg
15
16 and age of less than 60 years. We also performed a subgroup analysis according to baseline
17
18 blood pressure levels (SBP/DBP: <120/<80, 120 to 129/<80, 130 to 139/80 to 89, 140 to
19
20 159/90 to 99, and $\geq 160/\geq 100$ mm Hg), where SBP/DBP of <120/<80 was treated as the
21
22 reference group.
23
24
25
26
27
28
29
30
31

32 All analyses were performed using R software (Version 3.5.1). All p-values for the tests were
33
34 two-sided and p-values<0.05 were considered as statistically significant.
35
36
37
38
39

40 Patient and public involvement

41
42 Patients or the public were not involved in the study.
43
44
45
46
47

48 Results

49
50 Of the 7,314 participants (aged 50.65 ± 11.8 years), the prevalence of hypertension was
51
52 30.02%. The proportion of people aged 60 years and above was higher in hypertensive
53
54 patients (36.75%) when compared with non-hypertensive participants (19.05%, $P < 0.001$). In
55
56 addition, hypertensive patients were less educated than non-hypertensive participants
57
58
59
60

($P<0.001$). Moreover, there were more participants with tobacco smoking (49.27% vs. 44.92%) and alcohol consumption (31.74% vs. 30.15%) among hypertensive patients when compared with non-hypertensive participants. Furthermore, the percentage of obesity was higher among hypertensive patients when compared with non-hypertensive participants ($P<0.001$) (Table 1).

Table 1 Characteristics of the participants by hypertensive status at baseline

	Hypertensive patients (n=2,196)	Non-hypertensive participants (n=5,118)	<i>P</i>
Age, n (%)			<0.001
<60	1,389 (63.25)	4,143 (80.95)	
≥60	807 (36.75)	975 (19.05)	
Sex, n (%)			<0.001
Male	1,002 (45.63)	2,344 (45.80)	
Female	1,194 (54.37)	2,774 (54.20)	
Education, n (%)			
Illiterate	805 (36.65)	1,224 (23.91)	
Primary	666 (30.33)	1,692 (33.06)	
Middle school	628 (28.60)	1,917 (37.46)	
High school and above	97 (4.42)	285 (5.57)	
Tobacco smoking, n (%)			<0.001
Non-smoking	1,114 (50.73)	2,819 (55.08)	
Ex-smoking	202 (9.20)	234 (4.57)	
Current smoking	880 (40.07)	2065 (40.35)	
Alcohol consumption, n (%)			<0.001
Non-drinking	1,499 (68.26)	3575 (69.85)	
Ex-drinking	510 (23.22)	1250 (24.42)	
Current drinking	187 (8.52)	293 (5.73)	
BMI (kg/m ²), n (%)			<0.001
BMI<18.5	48 (2.19)	91 (1.78)	
18.5≤BMI<23.9	956 (43.53)	2930 (57.25)	
24.0≤BMI<27.9	811 (36.93)	1752 (34.23)	
BMI≥28.0	381 (17.35)	345 (6.74)	

BMI: body mass index

1
2
3
4
5
6
7 During the median follow-up of 20 years, we identified 350 deaths from CVDs (148 stroke,
8
9 113 coronary heart disease, and 89 other CVDs). In the multivariable model adjusting for age,
10
11 sex, educational level, smoking, alcohol consumption, dietary salt intake, body mass index
12
13 (BMI), use of anti-hypertensive medications, and family history of hypertension, we detected
14
15 statistically significant association between hypertension and the risk of mortality from CVDs
16
17 (HR=1.35; 95% CI, 1.08 to 1.69). In the subgroup analysis based on baseline age, we found
18
19 that, for people aged 35-59 years, hypertensive patients had a higher risk of mortality from
20
21 CVDs when compared to those without hypertension (HR=2.49; 95% CI, 1.77 to 3.50) (Table
22
23 2). However, there was no significant association between hypertension and the risk of
24
25 mortality due to CVDs among people aged 60 years and over ($P>0.05$) (Table 2). Thus, age
26
27 may significantly modify the association between hypertension and risk of mortality from
28
29 CVDs (P for interaction <0.001).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Multivariable hazard ratios (HRs) of mortality from cardiovascular diseases according to baseline history of hypertension

		CVDs mortality			
		N	Deaths	Adjusted HR (95% CI)	P
Total					
Baseline hypertension status					
No	5118	189	Reference		
Yes	2196	161	1.35 (1.08 to 1.69)	0.01	
Age < 60 years					
Baseline hypertension status					
No	4143	80	Reference		
Yes	1389	64	2.49 (1.77 to 3.50)	<0.001	
Age ≥ 60 years					
Baseline hypertension status					
No	975	109	Reference		
Yes	807	97	1.01 (0.76 to 1.33)	0.96	

CVDs: cardiovascular diseases; HR: hazard ratio; CI: confidence interval

In the subgroup analysis according to different baseline blood pressure, the results showed that hypertensive patients with SBP/DBP of 140-159/90-99 and $\geq 160/100$ mm Hg were more likely to die of CVDs (HR=1.44; 95% CI, 1.02 to 2.03; HR=1.74; 95% CI, 1.22 to 2.48) when compared with participants with SBP/DBP of <120/80 mm Hg. However, we failed to detect significant associations between SBP/DBP of 130-139/80-89 mm Hg (HR=1.18; 95% CI, 0.85 to 1.64, $P=0.32$) and 120-129/<80 mm Hg (HR=1.38; 95% CI, 0.93 to 2.05, $P=0.11$) and the risk of mortality from CVDs, respectively. Further, among participants aged <60 years at

baseline, similar trend was observed between hypertension and the risk of mortality due to CVDs, where HR was 2.32 ($P<0.001$) for SBP/DBP of 140-159/90-99 mm Hg and 3.25 ($P<0.001$) for $\geq 160/100$ mm Hg, respectively. However, there was no significant association between hypertension and the risk of mortality from CVDs with different baseline blood pressure levels for those aged ≥ 60 years (P for interaction <0.001) (Table 3).

Table 3 Multivariable hazard ratios (HRs) of mortality from cardiovascular diseases according to baseline blood pressure levels

	CVDs mortality			
	N	Deaths	Adjusted HR (95% CI)	<i>P</i>
Total				
<120/80	2132	61	Reference	
120-129/<80	920	43	1.38 (0.93 to 2.05)	0.11
130-139/80-89	2180	91	1.18 (0.85 to 1.64)	0.32
140-159/90-99	1239	80	1.44 (1.02 to 2.03)	0.04
$\geq 160/100$	843	75	1.74 (1.22 to 2.48)	<0.01
Age<60 years				
<120/80	1813	32	Reference	
120-129/<80	727	21	1.46 (0.84 to 2.55)	0.18
130-139/80-89	1691	29	0.90 (0.54 to 1.50)	0.70
140-159/90-99	818	34	2.31 (1.41 to 3.79)	<0.001
$\geq 160/100$	483	28	3.25 (1.92 to 5.50)	<0.001
Age ≥ 60 years				
<120/80	319	29	Reference	
120-129/<80	193	22	1.28 (0.74 to 2.24)	0.38
130-139/80-89	489	62	1.47 (0.94 to 2.29)	0.09
140-159/90-99	421	46	1.16 (0.72 to 1.85)	0.55
$\geq 160/100$	360	47	1.41 (0.88 to 2.26)	0.16

CVDs: cardiovascular diseases; HR: hazard ratio; CI: confidence interval

Discussion

The present 20-year prospective study filled the gaps for implying the generalizability of the 2017 ACC/AHA Hypertension Guideline to Chinese populations. The results showed there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA and CVDs mortality when compared with SBP/DBP of <120/80. In addition, we detected high blood pressure was associated with higher mortality from CVDs among people aged 35-59 years rather than those aged 60 years and over. The findings may contribute to the optimal management of hypertension to address the growing burden of CVDs morbidity and mortality in China, suggesting a large implication both to clinicians and public health practitioners.

ACC/AHA Task Force on Clinical Practice Guidelines released the 2017 hypertension guideline, which defined a SBP of 130 to 139 mm Hg or DBP of 80 to 89 mm Hg as stage 1 hypertension supported by the evidence from SPRINT [6,8]. Based on the new criterion, the prevalence of hypertension would increase substantially in many countries [14-16]. Although intensive blood pressure control was beneficial to cardiovascular events and total mortality, it was associated with an increased number of newly diagnosed hypertensive patients who may not develop CVD events in the future [14]. In particular, with a large aging population, there was a high prevalence of hypertension in China [17-19]. Besides, it is estimated that uncontrolled hypertension was responsible for 750000 CVD deaths in China in 2010 [3]. Furthermore, contrary to western countries that CVD mortality has decreased significantly during the past years, CVD mortality has increased during the same period in China [3,20]. Thus, whether the results of SPRINT apply to Chinese populations is a critical question to

1
2
3
4 answer. In the current study, we estimated the associations of different blood pressure levels
5
6 with consequent CVD mortality to provide more evidence among Chinese populations aged
7
8 35 years or above.
9

10
11
12
13
14 Firstly, we examined the association between hypertension of $\geq 140/90$ mm Hg and the risk
15
16 of mortality from CVDs, which showed a higher risk of mortality from CVDs in hypertensive
17
18 patients when compared with non-hypertensive participants (HR=1.35). The CVDs mortality
19
20 burden attributable to hypertension has increased in China in recent years [4,20-22], and a
21
22 previous study found that 2.11 million CVDs deaths were caused by hypertension [21].
23
24
25

26
27
28
29
30 In the analysis by different blood pressure levels at baseline, the HR of CVDs mortality
31
32 related to stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline (130-
33
34 139/80-89 mm Hg) was not statistically higher than that related to SBP/DBP of $<120/<80$ mm
35
36 Hg in our study. Previous studies have demonstrated diagnosed hypertensive patients tended
37
38 to prescribe antihypertensive medications despite the lifestyle modifications management
39
40 suggestions [15,23], which may increase adverse effects caused by anti-hypertension
41
42 treatment among the newly diagnosed patients such as acute kidney injury, acute renal failure,
43
44 hypotension, syncope, or electrolyte abnormality [13,24]. In addition, the higher hypertension
45
46 diagnosis costs due to treatment is another important issue [24,25]. Since there was a lack of
47
48 awareness, adherence to hypertension guidelines, as well as access to antihypertensive drugs
49
50 in China, the health and cost-effectiveness of the new diagnostic criteria for hypertension
51
52 should be evaluated further. Thus, the results in our study may help address the current
53
54
55
56
57
58
59
60

1
2
3
4 evidence gaps about whether the 2017 ACC/AHA guideline could be applied to populations
5
6 in rural China.
7
8
9

10
11 Further, we conducted a subgroup analysis to explore the association between hypertension
12 and the risk of mortality from CVDs according to different age groups, and the results showed
13 that the associations between hypertension and CVDs mortality were stronger among
14 participants aged 35-59 years than those aged 60 years and above. A previous study also
15 showed a significant interaction between age and hypertension for the risk of mortality from
16 CVDs, where the association between hypertension and the risk of CVDs mortality was
17 significant in the age groups of 35 to 44 and 45 to 59 years rather than in the group of ≥ 60
18 years [12]. Besides, a study based on pooling data from 7 diverse US cohort studies showed
19 that individuals who experienced blood pressure increases prior to middle age have associated
20 higher remaining lifetime risk for CVDs when compared with those who had developed
21 hypertension later in age 55 [26]. Similarly, a previous meta-analysis of 13 prospective cohort
22 studies involving 396,200 participants showed that pre-hypertension was not associated with
23 CVDs risk among older populations with age ≥ 60 years [27]. It is reported that the
24 cardiovascular risk for hypertensive patients decreased as age of onset increased from 40 to
25 69 years [28]. Possible explanations for the age-specific association between hypertension
26 and the risk of mortality from CVDs needs further studies. In addition, it is important to
27 consider the influence of age in the diagnosis of hypertension.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The 20-year prospective study included a relatively large sample size examining the

1
2
3
4 association between high blood pressure and the risk of mortality from CVDs. A previous
5
6 study suggested a north-south gradient in the mortality of CVDs due to the difference in
7
8 prevalence of hypertension in China [29]. Furthermore, the Sino-MONICA study showed that
9
10 the number of deaths caused by stroke was larger than that caused by coronary heart disease
11
12 [30]. In addition, 73% of the stroke burden could be attributed to hypertension in China, and
13
14 prevalence of hypertension in stroke survivors in China was relatively high when compared
15
16 with other countries [31]. Fangshan District is located in the "stroke belt" of China [32]. Thus,
17
18 the study is important to elucidate the association between stage 1 hypertension defined by
19
20 the 2017 ACCAHA Hypertension Guideline and cardiovascular deaths in rural China.
21
22
23
24
25
26
27
28
29

30 Nevertheless, the study has several limitations. Firstly, we cannot exclude the influence of
31
32 some potential confounding factors despite we conducted the analysis with careful adjustment.
33
34 Secondly, hypertension was defined by SBP/DBP at baseline while we failed to acquire blood
35
36 pressure measurements during follow-up, which may underestimate the strength of the
37
38 associations we observed. Next, we had insufficient sample size to explore whether the effects
39
40 of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or
41
42 chronic kidney disease. In addition, information of death was obtained from the Death
43
44 Surveillance System, the participants lost to follow-up were hard to detect and may cause
45
46 potential bias. Therefore, further studies with a larger sample size are needed to validate the
47
48 results in the study.
49
50
51
52
53
54
55
56
57

58 **Conclusion**

1
2
3
4 In conclusion, the current study revealed hypertension of $\geq 140/90$ mm Hg was an important
5
6 risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage
7
8 1 hypertension under the definition of 2017 ACC/AHA was not associated with increased risk
9
10 of CVDs mortality. This study indicated that whether adopting the new hypertension
11
12 definition needs further consideration in rural China.
13
14
15
16
17
18

19 **Competing interests**

20
21
22 The authors declare that they have no competing interests.
23
24
25
26

27 **Founding**

28
29 This work was supported by the Key Project of Natural Science Funds of China (81230066)
30
31 and National Natural Science Foundation of China (81473043, 81502874, 81573226,
32
33 81703291).
34
35
36
37
38
39

40 **Contributorship statement**

41
42 MW, TW, and YH conceived and designed the paper. LL, WC, JL, YW, XQ, XT, QZ, SH, SZ,
43
44 YH, TW, and DY coordinated the data acquisition and contributed to critical revision of the
45
46 manuscript for important intellectual content. MW, PG, WG, and CY analyzed the data. MW
47
48 and TW drafted the manuscript. MW, TW, LL, and YH and were responsible for the overall
49
50 content of article and data analysis. The manuscript is approved by all authors for publication.
51
52
53
54
55
56
57

58 **References**

1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. *JAMA* 2017;317:165-182.
2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. *Circulation* 2016;134:441-50.
3. Lewington S, Lacey B, Clarke R, Guo Y, Kong XL, Yang L, et al. The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China. *JAMA Intern Med* 2016;176:524-32.
4. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet* 2014;384:591-598.
5. Angell SY, De Cock KM, Frieden TR. A public health approach to global management of hypertension. *Lancet* 2015;385:825-7.
6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;71:e127-e248.
7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018;39:3021-3104.

- 1
2
3
4 8. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure
5
6 control. *N Engl J Med* 2015;373:2103-2116.
7
8
- 9 9. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic Blood Pressure
10
11 Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and
12
13 Network Meta-analysis. *JAMA Cardiol* 2017;2:775-781.
14
15
- 16 10. Kulenthiran S, Ewen S, Böhm M, Mahfoud F. Hypertension up to date: SPRINT to
17
18 SPYRAL. *Clin Res Cardiol* 2017;106:475-484.
19
20
- 21 11. Sun X, Guo Y, Nie Z, Cheng J, Zhou H, Zhong X, et al. Influence of baseline systolic blood
22
23 pressure on the relationship between intensive blood pressure control and cardiovascular
24
25 outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT). *Clin Res Cardiol*
26
27 2019;108:273-281.
28
29
- 30 12. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive
31
32 Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *N Engl J Med*
33
34 2016;375:1033-43.
35
36
- 37 13. Qi Y, Han X, Zhao D, Wang W, Wang M, Sun J, et al. Long-Term Cardiovascular Risk
38
39 Associated With Stage 1 Hypertension Defined by the 2017 ACC/AHA Hypertension
40
41 Guideline. *J Am Coll Cardiol* 2018;72:1201-1210.
42
43
- 44 14. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the Association of the
45
46 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US
47
48 Adults: An Analysis of National Data. *JAMA Cardiol* 2018;3:572-581.
49
50
- 51 15. Dorans KS, Mills KT, Liu Y, He J. Trends in Prevalence and Control of Hypertension
52
53 According to the 2017 American College of Cardiology/American Heart Association
54
55
56
57
58
59
60

- (ACC/AHA) Guideline. *J Am Heart Assoc* 2018;7. pii: e008888.
16. Kibria GMA, Swasey K, Choudhury A, Burrowes V, Stafford KA, Uddin SMI, et al. The new 2017 ACC/AHA guideline for classification of hypertension: changes in prevalence of hypertension among adults in Bangladesh. *J Hum Hypertens* 2018;32:608-616.
 17. National Bureau of Statistics of the People's Republic of China. The Sixth National Population Census of the People's Republic of China. 2010. Available at: <http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/in>. Accessed December 5, 2018.
 18. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). *Lancet* 2017;390:2549-58.
 19. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. *Circulation* 2018;137:2344-56.
 20. Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. *Lancet* 2016;387:251-72.
 21. He J, Gu D, Chen J, Wu X, Kelly TN, Huang J, et al. Premature deaths attributable to blood pressure in China: a prospective cohort study. *Lancet* 2009;374:1765-72.
 22. Bundy JD, He J. Hypertension and related cardiovascular disease burden in China. *Ann Glob Health* 2016;82:227-33.
 23. Wang JG, Liu L. Global Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From China. *Circulation*

- 1
2
3
4 2018;137:546-548.
5
6
7 24. Bakris G, Sorrentino M. Redefining Hypertension-Assessing the New Blood-Pressure
8
9 Guidelines. *N Engl J Med* 2018;378:497-499.
10
11
12 25. Gijón-Conde T, Sánchez-Martínez M, Graciani A, Cruz JJ, López-García E, Ortolá R, et
13
14 al. Impact of the European and American guidelines on hypertension prevalence, treatment,
15
16 and cardiometabolic goals. *J Hypertens* 2019;37:1393-1400.
17
18
19 26. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood
20
21 pressure and blood pressure change during middle age on the remaining lifetime risk for
22
23 cardiovascular disease: the cardiovascular lifetime risk pooling project. *Circulation*
24
25 2012;125:37-44.
26
27
28
29 27. Wang S, Wu H, Zhang Q, Xu J, Fan Y. Impact of baseline prehypertension on
30
31 cardiovascular events and all-cause mortality in the general population: a meta-analysis of
32
33 prospective cohort studies. *Int J Cardiol* 2013;168:4857-60.
34
35
36
37 28. Buck C, Baker P, Bass M, Donner A. The prognosis of hypertension according to age at
38
39 onset. *Hypertension* 1987;9:204-208.
40
41
42
43 29. Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J, et al. Epidemiological transition of stroke
44
45 in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project.
46
47 *Stroke* 2008;39:1668-74.
48
49
50
51 30. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA Project: a collaborative
52
53 study on trends and determinants in cardiovascular diseases in China, part I: morbidity and
54
55 mortality monitoring. *Circulation* 2001;103:462-8.
56
57
58
59 31. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, Incidence, and Mortality
60

1
2
3
4 of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults.

5
6 *Circulation* 2017;135:759-771.

- 7
8
9 32. Tang X, Hu Y, Chen D, Zhan S, Zhang Z, Dou H. The Fangshan/Family-based Ischemic
10
11 Stroke Study In China (FISSIC) protocol. *BMC Med Genet* 2007;8:60.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	<p>(a) Page 1, page 2, and page 3. The study was a prospective cohort study, which was conducted to explore the association between blood pressure and cardiovascular diseases mortality.</p> <p>The title was: The association between stage 1 hypertension defined by the 2017 ACCAHA Hypertension Guideline and cardiovascular deaths: a 20-year follow-up study in rural China</p> <p>(b) Page 2 and page 3. The abstract gave a brief introduction of the objectives, methods, results, and conclusions of the study.</p>
Introduction		
Background/rationale	2	Page 5 and page 6. In the introduction section, we demonstrated that the optimal blood pressure, particularly for systolic blood pressure (SBP) treatment target is unclear worldwide. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults recommended 130/80 mmHg as blood pressure target goals. However, the generalizability of SPRINT findings to populations at large with hypertension remains controversial.
Objectives	3	Page 6. We aimed to assess the relative risk of CVDs mortality associated with different stages of hypertension according to 2017 ACC/AHA using a 20-year follow-up study in China, to further evaluate the generalizability of SPRINT findings and explore the target blood pressure levels among Chinese populations.
Methods		
Study design	4	Page 6. As stated it in the Methods section, our study was a prospective cohort study.
Setting	5	Page 6. The study was a community-based follow-up study for the prevention and treatment of hypertension, which is being conducted in Fangshan District, Beijing, China.
Participants	6	Page 6 and page 7. As described in the Methods section about the participants, from month 1996/1997 through month 1998/1999, 8,189 participants aged 35 to 97 years were enrolled. Informed consent was obtained from all participants. In addition, the study was approved by the Institutional Review Board of Peking University Health Science Center.
Variables	7	<p>Page 7.</p> <p>The primary outcome variable was death from CVDs. The information of death was continuously obtained from the Death Surveillance System in the Center for Disease Prevention and Control in Fangshan District. Date of death was ascertained from the record in the system. We determined survival times from the date participants investigated in the baseline survey through December 31, 2017. Participants who were alive at the end of this period contributed with censored observations to the survival analyses of time to death. The causes of death were coded using the International Classification of Diseases, Ninth Revision (ICD-9) codes from 1997 to 2001, and International Classification of Diseases, Tenth Revision (ICD-10) codes from 2002-2017.</p>
Data sources/	8*	The primary exposure variables for these analyses included age at the enrollment

measurement

and the blood pressure level at baseline. Data on sociodemographic characteristics, lifestyles, and medical history of the participants were collected through questionnaire interview by trained staff members.

Participants were defined as never smokers, former smokers, and current smokers. Information on alcohol consumption was obtained through asking the participants to describe their drinking status: never, light (less than 2 drinks a day), or heavy (≥ 2 drinks a day). Further, the salt intake of the participants was assessed according to the question of what kind of taste they liked (salty taste, moderate, or light taste).

Physical measurements included height, weight, and blood pressure. Blood pressure levels were measured 3 times using a mercury sphygmomanometer by trained investigators. The mean of the 3 recorded measurements were included in the analysis. Hypertension was defined as SBP ≥ 140 mm Hg, systolic blood pressure (DBP) ≥ 90 mm Hg, self-reported antihypertensive medication in the past 2 weeks, or self-reported history of hypertension.

Bias	9	Page and page 9. Potential confounders may exist despite careful adjustment for potential confounders in the analysis.
Study size	10	Page 7. A total of 7,314 participants (3,346 males and 3,968 females) were included in the analysis.
Quantitative variables	11	Page 9. Age and BMI were handled as quantitative variables in the models.
Statistical methods	12	(a) Page 8 and page 9. Student's t-test and Chi-square test were used to test the differences between different baseline hypertensive history groups for continuous variables and categorical variables, respectively. Person-years for each participant were calculated as the duration from the survey date at baseline through death date or date of lost to follow-up, whichever came first. The Cox proportional hazards regression model for CVDs death included baseline blood pressure level, age, sex, education level, body mass index, smoking status, alcohol use, dietary salt intake, antihypertensive medications, and family history of hypertension. Participants were classified as two groups according to baseline hypertensive status, and non-hypertension (<140/90 mmHg) was treated as reference. (b) Page 9. To test for possible interactions between age and hypertension, we categorized age with cutoffs of 60 years and hypertension as binary variables, and setting variable cross-product terms of hypertension (yes/no) with age (<60 and ≥ 60 years) in the model. Reference groups were SBP/DBP of less than 140/90 mm Hg and age of less than 60 years. We also performed a subgroup analysis according to baseline blood pressure levels (SBP/DBP: <120/<80, 120 to 129/<80, 130 to 139/80 to 89, 140 to 159/90 to 99, and $\geq 160/\geq 100$ mm Hg), where SBP/DBP of <120/<80 was treated as the reference group. (c) There was no missing data in the analysis since standard quality control criteria were adopted in our study. (d) Not applicable (e) We did not conduct any sensitivity analyses

Continued

on

next

page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Page 7. Our study only had one stage, and all 7,314 participants were included in the analysis. (b) Not applicable (c) Not applicable
Descriptive data	14*	(a) Page 9 and page 10. Of the 7,314 participants (aged 50.65±11.8 years), the prevalence of hypertension was 30.02%. The proportion of people aged 60 years and above was higher in hypertensive patients (36.75%) when compared with non-hypertensive participants (19.05%, P<0.001). In addition, hypertensive patients were less educated than non-hypertensive participants (P<0.001). Moreover, there were more participants with tobacco smoking (49.27% vs. 44.92%) and alcohol consumption (31.74% vs. 30.15%) among hypertensive patients when compared with non-hypertensive participants. Furthermore, the percentage of obesity was higher among hypertensive patients when compared with non-hypertensive participants (P<0.001). (b) Not applicable
Outcome data	15*	Page 10 and page 11. During the median follow-up of 20 years, we identified 350 deaths from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs).
Main results	16	(a) Page 11 and page 12. We detected statistically significant association between hypertension and the risk of mortality from CVDs (HR=1.35; 95% CI, 1.08 to 1.69). In the subgroup analysis based on baseline age, we found that, for people aged 35-59 years, hypertensive patients had a higher risk of mortality from CVDs when compared to those without hypertension (HR=2.49; 95% CI, 1.77 to 3.50). (b) Page 11 and page 12. There was no significant association between hypertension and the risk of mortality due to CVDs among people aged 60 years and over (P>0.05). Thus, age may significantly modify the association between hypertension and risk of mortality from CVDs (P for interaction<0.001). (c) Not applicable
Other analyses	17	Page 12 and page 13. Hypertensive patients with SBP/DBP of 140-159/90-99 and ≥160/100 mm Hg were more likely to die of CVDs (HR=1.44; 95% CI, 1.02 to 2.03; HR=1.74; 95% CI, 1.22 to 2.48) when compared with participants with SBP/DBP of <120/80 mm Hg. However, we failed to detect significant associations between SBP/DBP of 130-139/80-89 mm Hg (HR=1.18; 95% CI, 0.85 to 1.64, P=0.32) and 120-129/<80 mm Hg (HR=1.38; 95% CI, 0.93 to 2.05, P=0.11) and the risk of mortality from CVDs, respectively. Further, among participants aged<60 years at baseline, similar trend was observed between hypertension and the risk of mortality due to CVDs, where HR was 2.32 (P<0.001) for SBP/DBP of 140-159/90-99 mm Hg and 3.25 (P<0.001) for ≥160/100 mm Hg, respectively. However, there was no significant association between hypertension and the risk of mortality from CVDs with different baseline blood pressure levels for those aged≥60 years (P for interaction<0.001).

Discussion

Key results	18	Page 14, page 15, and page 16. The present 20-year prospective study filled the gaps for implying the generalizability of the 2017 ACC/AHA Hypertension Guideline to Chinese populations. The results showed there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA and CVDs mortality when compared with SBP/DBP of <120/80. In addition, we detected high blood pressure was associated with higher mortality from CVDs among people aged 35-59 years rather than those aged 60 years and over. The findings may contribute to the optimal management of hypertension to address the
-------------	----	---

growing burden of CVDs morbidity and mortality in China, suggesting a large implication both to clinicians and public health practitioners.

Limitations	19	Page 17. Firstly, we cannot exclude the influence of some potential confounding factors despite we conducted the analysis with careful adjustment. Secondly, hypertension was defined by SBP/DBP at baseline while we failed to acquire blood pressure measurements during follow-up, which may underestimate the strength of the associations we observed. Next, we had insufficient sample size to explore whether the effects of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or chronic kidney disease. In addition, information of death was obtained from the Death Surveillance System, the participants lost to follow-up were hard to detect and may cause potential bias. Therefore, further studies with a larger sample size are needed to validate the results in the study.
Interpretation	20	Page 14, page 15, and page 16. From an objective perspective, we discussed the results from the aspects recommended in the STROBE Checklist.
Generalisability	21	Page 18. The current study revealed hypertension of $\geq 140/90$ mm Hg was an important risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage 1 hypertension under the definition of 2017 ACC/AHA was not associated with increased risk of CVDs mortality. This study indicated that whether adopting the new hypertension definition needs further consideration in rural China.

Other information

Funding 22 Page 18. All sources of funding were described in the Acknowledgement section.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The association between blood pressure levels and cardiovascular deaths: a 20-year follow-up study in rural China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035190.R1
Article Type:	Original research
Date Submitted by the Author:	07-Jan-2020
Complete List of Authors:	Wang, Mengying; Peking University, Epidemiology and Biostatistics Wu, Tao; Peking University, Epidemiology and Biostatistics Yu, Canqing; Peking University, Epidemiology and Biostatistics Gao, Wenjing; Peking University, Epidemiology and Biostatistics Lv, Jun; Peking University, Epidemiology and Biostatistics Wu, Yiqun; Peking University, Epidemiology and Biostatistics Qin, Xueying; Peking University, Epidemiology and Biostatistics TANG, Xun; Peking University, Epidemiology and Biostatistics Gao, Pei; Peking University, Epidemiology and Biostatistics Zhan, Siyan; Peking University, Epidemiology and Biostatistics Cao, Weihua; Peking University, Epidemiology and Biostatistics Zhao, Qingshui; General Office Huang, Shaoping; General Office Yang, Dongli; General Office LI, Li-ming; Peking University, Epidemiology and Biostatistics Hu, Yong-Hua; Peking University, Epidemiology and Biostatistics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Evidence based practice
Keywords:	Hypertension < CARDIOLOGY, Stroke < NEUROLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The association between blood pressure levels and cardiovascular deaths: a 20-year follow-up
study in rural China

Mengying Wang¹, Tao Wu^{1*}, Canqing Yu¹, Wenjing Gao¹, Jun Lv¹, Yiqun Wu¹, Xueying
Qin¹, Xun Tang¹, Pei Gao¹, Siyan Zhan¹, Weihua Cao¹, Qingshui Zhao², Shaoping Huang²,
Dongli Yang³, Liming Li¹, Yonghua Hu¹

E-mail address for authors

Mengying Wang: 1461589478@qq.com; Tao Wu: twu@bjmu.edu.cn;

Canqing Yu: yucanqing@pku.edu.cn; Wenjing Gao: pkugwj@qq.com;

Jun Lv: lvjun@bjmu.edu.cn; Yiqun Wu: qywu118@163.com;

Xueying Qin: xueyingqin@bjmu.edu.cn; Xun Tang: tangxun@bjmu.edu.cn;

Pei Gao: pei_gao@163.com; Siyan Zhan: siyan-zhan@bjmu.edu.cn;

Weihua Cao: caoweihua60@163.com; Qingshui Zhao: zqs_67189@163.com;

Shaoping Huang: 2146733477@qq.com; Dongli Yang: 2178757723@qq.com;

Liming Li: lmlee@vip.163.com; Yonghua Hu: yhhu@bjmu.edu.cn

¹Department of Epidemiology and Biostatistics, School of Public Health, Peking University

² Department of General Office, Fangshan District Center for Disease Control and Prevention,
Beijing, China

³ Department of General Office, Fangshan District Health Commission, Beijing, China

Corresponding to:

Tao Wu, Department of Epidemiology and Biostatistics, School of Public Health, Peking
University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing, China, 100191.

E-mail: twu@bjmu.edu.cn

Abstract

Objectives: The 2017 ACC/AHA Hypertension Guideline recommended 130/80 mmHg as blood pressure (BP) target goals. However, the generalizability of this recommendation to populations at large with hypertension remains controversial. We assessed the association between BP and cardiovascular diseases (CVDs) mortality using a 20-year follow-up study among Chinese populations.

Design: Prospective cohort study.

Participants: 7,314 participants were followed up for a median of 20 years in Fangshan District, Beijing, China.

Methods: The primary outcome variable was death from cardiovascular causes. The adjusted hazard ratio (HR) for CVDs mortality associated with baseline BP was calculated using Cox regression analysis.

Results: We identified 350 deaths from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs) during follow-up. Hypertension (defined by systolic BP (SBP) /diastolic BP (DBP) $\geq 140/90$ mm Hg) was significantly associated with mortality due to CVDs (HR=2.49, 95% CI=1.77-3.50) among people aged 35-59 years rather than people aged ≥ 60 . In addition, there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA (SBP/DBP of 130-139/80-89 mm Hg) and CVDs mortality when compared with SBP/DBP of $<120/80$ in neither the participants aged <60 years (HR=0.90, 95% CI=0.54-1.50) nor participants aged ≥ 60 years (HR=1.47, 95% CI=0.94-2.29).

Conclusion: The study revealed hypertension of SBP/DBP $\geq 140/90$ mm Hg was an important risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage

1
2
3
4 1 hypertension under the definition of 2017 ACC/AHA was not associated with an increased
5
6 risk of CVDs mortality. This study indicated that whether adopting the new hypertension
7
8 definition needs further consideration in rural Chinese populations.
9
10

11 **Keywords:** hypertension; mortality; cardiovascular diseases; cohort study
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

1. The prospective study had a relatively long follow-up time of 20 years.
2. The study examined the association between high blood pressure and mortality from CVDs, which were hard outcomes.
3. Hypertension was defined by systolic blood pressure or diastolic blood pressure at baseline while we failed to acquire blood pressure measurements during follow-up, which may underestimate the strength of the associations we observed.
4. Whether the effects of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or chronic kidney disease was not explored due to limited data.
5. The information of death was obtained from the Death Surveillance System, the participants lost to follow-up were hard to detect and may cause potential bias.

Introduction

Hypertension is the first risk factor of cardiovascular diseases (CVDs), accounted for 7.8 million deaths and 148 million disability life years lost worldwide in 2015 [1]. It has been reported that hypertension affected nearly 30% of the adult population in Western countries as well as in China [2,3].

The management of high blood pressure is a public health priority with implications for the prevention of CVDs [4,5]. However, the optimal blood pressure, particularly for systolic blood pressure (SBP) treatment target is unclear worldwide. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults recommended 130/80 mmHg as blood pressure target goals [6]. However, the definition of hypertension remains $\geq 140/90$ mm Hg in the European guideline [7].

The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated intensive SBP lowering in adults without diabetes or stroke could result in significant decreases in cardiovascular events and all-cause mortality [8]. A network meta-analysis conducted by Bundy et al also suggested that a more intensive treatment target (eg, SBP of 120-124 mm Hg) showed improvement in the prevention of CVD complications and total mortality when compared with a standard SBP target (<140 mm Hg) [9]. However, the generalizability of SPRINT findings to populations at large with hypertension remains controversial [9-13]. For example, a recent study showed that the treatment to achieve a target SBP of 110 to 139 mm

1
2
3
4 Hg did not result in a lower rate of death than standard reduction to a target of 140 to 179
5
6 mmHg in hypertensive patients with intracerebral hemorrhage [12].
7
8
9

10
11 Here, we aimed to assess the relative risk of CVDs mortality associated with different stages
12
13 of hypertension according to 2017 ACC/AHA using a 20-year follow-up study in China, to
14
15 further evaluate the generalizability of SPRINT findings and explore the target blood pressure
16
17 levels among Chinese populations.
18
19
20
21
22

23 24 **Methods**

25 26 **Study design**

27
28 The participants for these analyses came from a community-based follow-up study for the
29
30 prevention and treatment of hypertension, which is being conducted in Fangshan District,
31
32 Beijing, China. Verbal informed consent was obtained from all participants. In addition, the
33
34 study was approved by the Institutional Review Board of Peking University Health Science
35
36 Center.
37
38
39
40
41
42
43
44
45

46 **Inclusion and exclusion of the participants**

47
48 From January 1997 through June 1999, 8,189 participants aged 35 to 97 years were enrolled.
49
50 We excluded 669 individuals with CVDs at baseline. In addition, we dropped the participants
51
52 if any of the key variables required in the analysis (blood pressure, height, weight,
53
54 demographic variables, or potential risk factors including smoking, alcohol consumption, or
55
56 high salt intake) was missing. Finally, a total of 7,314 participants (3,346 males and 3,968
57
58
59
60

1
2
3
4 females) were included in the analysis.
5
6
7
8

9 **Outcomes variables**

10
11 The primary outcome variable was death from CVDs. The information of death was
12 continuously obtained from the Death Surveillance System in the Center for Disease
13 Prevention and Control in Fangshan District. Date of death was ascertained from the record
14 in the system. We determined survival times from the date participants investigated in the
15 baseline survey through December 31, 2017. Participants who were alive at the end of this
16 period contributed with censored observations to the survival analyses of time to death. The
17 causes of death were coded using the International Classification of Diseases, Ninth Revision
18 (ICD-9) codes from 1997 to 2001, and International Classification of Diseases, Tenth
19 Revision (ICD-10) codes from 2002-2017.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection**

39
40 The primary exposure variables for these analyses included age at the enrollment and the
41 blood pressure level at baseline. Data on sociodemographic characteristics, lifestyles, and
42 medical history of the participants were collected through questionnaire interview by trained
43 staff members.
44
45
46
47
48
49
50
51
52

53 Participants were defined as never smokers, former smokers, and current smokers.
54 Information on alcohol consumption was obtained through asking the participants to describe
55 their drinking status: never, light (less than 2 drinks a day), or heavy (≥ 2 drinks a day). Further,
56
57
58
59
60

1
2
3
4 the salt intake of the participants was assessed according to the question of what kind of taste
5
6 they liked (salty taste, moderate, or light taste).
7
8
9

10
11 Physical measurements included height, weight, and blood pressure. Blood pressure levels were
12
13 measured 3 times using a mercury sphygmomanometer by trained investigators. The mean of
14
15 the 3 recorded measurements were included in the analysis.
16
17
18

19
20
21
22 Hypertension was defined as SBP ≥ 140 mm Hg, systolic blood pressure (DBP) ≥ 90 mm Hg,
23
24 self-reported antihypertensive medication in the past 2 weeks, or self-reported history of
25
26 hypertension [3]. In addition, according to the 2017 ACC/AHA guidelines, the participants
27
28 were divided into four categories: normal blood pressure (SBP < 120 mm Hg and DBP < 80 mm
29
30 Hg), elevated blood pressure ($120 \text{ mm Hg} \leq \text{SBP} \leq 129 \text{ mm Hg}$ and DBP < 80 mm Hg), stage 1
31
32 hypertension ($130 \text{ mm Hg} \leq \text{SBP} \leq 139 \text{ mm Hg}$ or $80 \leq \text{DBP} \leq 89 \text{ mm Hg}$), and stage 2
33
34 hypertension (SBP ≥ 140 mm Hg/DBP ≥ 90 mm Hg or taking antihypertensive medications).
35
36
37
38
39
40
41

42 **Statistical analysis**

43
44
45 Student's t-test and Chi-square test were used to test the differences between different baseline
46
47 hypertensive history groups for continuous variables and categorical variables, respectively.
48
49
50

51
52
53 Person-years for each participant were calculated as the duration from the survey date at
54
55 baseline through death date or date of lost to follow-up, whichever came first. The Cox
56
57 proportional hazards regression model for CVDs death included baseline blood pressure level,
58
59
60

1
2
3
4 age, sex, education level, body mass index, smoking status, alcohol use, dietary salt intake,
5
6 antihypertensive medications, and family history of hypertension. Participants were classified
7
8 as two groups according to baseline hypertensive status, and non-hypertension (<140/90
9
10 mmHg) was treated as reference. To test for possible interactions between age and
11
12 hypertension, we categorized age with cutoffs of 60 years and hypertension as binary
13
14 variables, and setting variable cross-product terms of hypertension (yes/no) with age (<60
15
16 and ≥ 60 years) in the model. Reference groups were SBP/DBP of less than 140/90 mm Hg
17
18 and age of less than 60 years. We also performed a subgroup analysis according to baseline
19
20 blood pressure levels (SBP/DBP: <120/<80, 120 to 129/<80, 130 to 139/80 to 89, 140 to
21
22 159/90 to 99, and $\geq 160/\geq 100$ mm Hg), where SBP/DBP of <120/<80 was treated as the
23
24 reference group.
25
26
27
28
29
30
31
32
33
34

35 All analyses were performed using R software (Version 3.5.1). All p-values for the tests were
36
37 two-sided and p-values < 0.05 were considered as statistically significant.
38
39
40
41
42

43 Patient and public involvement

44
45 Patients or the public were not involved in the study.
46
47
48
49

50 **Results**

51
52
53 Of the 7,314 participants (aged 50.65 ± 11.8 years), the prevalence of hypertension was
54
55 30.02%. The proportion of people aged 60 years and above was higher in hypertensive
56
57 patients (36.75%) when compared with non-hypertensive participants (19.05%, $P < 0.001$). In
58
59
60

1
2
3
4 addition, hypertensive patients were less educated than non-hypertensive participants
5
6 ($P<0.001$). Moreover, there were more participants with tobacco smoking (49.27% vs.
7
8 44.92%) and alcohol consumption (31.74% vs. 30.15%) among hypertensive patients when
9
10 compared with non-hypertensive participants. Furthermore, the percentage of obesity was
11
12 higher among hypertensive patients when compared with non-hypertensive participants
13
14 ($P<0.001$) (Table 1).
15
16
17
18

19 Table 1 Characteristics of the participants by hypertensive status at baseline

20	Hypertensive patients (n=2,196)	Non-hypertensive participants (n=5,118)	P
21			
22			
23			<0.001
24			
25			
26			
27			<0.001
28			
29			
30			
31			
32			<0.001
33			
34			
35			
36			
37			
38			
39			<0.001
40			
41			
42			
43			
44			
45			<0.001
46			
47			
48			
49			
50			
51			
52			<0.001
53			
54			
55			
56			
57			
58			

59
60

1
2
3
4 BMI: body mass index
5
6
7
8

9 During the median follow-up of 20 years, we have identified 609 deaths, of which 350 deaths
10 were from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs). In the
11 multivariable model adjusting for age, sex, educational level, smoking, alcohol consumption,
12 dietary salt intake, body mass index (BMI), use of anti-hypertensive medications, and family
13 history of hypertension, we detected statistically significant association between hypertension
14 and mortality from CVDs (HR=1.35; 95% CI, 1.08 to 1.69). In the subgroup analysis based
15 on baseline age, we found that, for people aged 35-59 years, hypertensive patients had a
16 higher risk of mortality from CVDs when compared to those without hypertension (HR=2.49;
17 95% CI, 1.77 to 3.50) (Table 2). However, there was no significant association between
18 hypertension and mortality due to CVDs among people aged 60 years and over ($P>0.05$)
19 (Table 2). Thus, age may significantly modify the association between hypertension and
20 mortality from CVDs (P for interaction <0.001). We also assessed the association between
21 hypertension and all-cause, coronary heart disease, and stroke mortality (Supplementary
22 Table 1).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Multivariable hazard ratios (HRs) of mortality from cardiovascular diseases

	CVDs mortality			
	N	Deaths	Adjusted HR (95% CI)	P
Total				
Baseline hypertension status				
No	5118	189	Reference	
Yes	2196	161	1.35 (1.08 to 1.69)	0.01
Age<60 years				
Baseline hypertension status				
No	4143	80	Reference	
Yes	1389	64	2.49 (1.77 to 3.50)	<0.001
Age≥60 years				
Baseline hypertension status				
No	975	109	Reference	
Yes	807	97	1.01 (0.76 to 1.33)	0.96

according to baseline history of hypertension

CVDs: cardiovascular diseases; HR: hazard ratio; CI: confidence interval

Stratified analysis according to different baseline blood pressure showed that hypertensive patients with SBP/DBP of 140-159/90-99 and $\geq 160/100$ mm Hg were more likely to die of CVDs (HR=1.44; 95% CI, 1.02 to 2.03; HR=1.74; 95% CI, 1.22 to 2.48) when compared with participants with SBP/DBP of <120/80 mm Hg. However, we failed to detect significant associations between SBP/DBP of 130-139/80-89 mm Hg (HR=1.18; 95% CI, 0.85 to 1.64, $P=0.32$) and 120-129/<80 mm Hg (HR=1.38; 95% CI, 0.93 to 2.05, $P=0.11$) and mortality from CVDs, respectively. Further, among participants aged<60 years at baseline, similar

trend was observed between hypertension and mortality due to CVDs, where HR was 2.32 ($P<0.001$) for SBP/DBP of 140-159/90-99 mm Hg and 3.25 ($P<0.001$) for $\geq 160/100$ mm Hg, respectively. However, there was no significant association between hypertension and mortality from CVDs with different baseline blood pressure levels for those aged ≥ 60 years (P for interaction <0.001) (Table 3).

Table 3 Multivariable hazard ratios (HRs) of mortality from cardiovascular diseases

	CVDs mortality			
	N	Deaths	Adjusted HR (95% CI)	<i>P</i>
Total				
<120/80	2132	61	Reference	
120-129/<80	920	43	1.38 (0.93 to 2.05)	0.11
130-139/80-89	2180	91	1.18 (0.85 to 1.64)	0.32
140-159/90-99	1239	80	1.44 (1.02 to 2.03)	0.04
$\geq 160/100$	843	75	1.74 (1.22 to 2.48)	<0.01
Age <60 years				
<120/80	1813	32	Reference	
120-129/<80	727	21	1.46 (0.84 to 2.55)	0.18
130-139/80-89	1691	29	0.90 (0.54 to 1.50)	0.70
140-159/90-99	818	34	2.31 (1.41 to 3.79)	<0.001
$\geq 160/100$	483	28	3.25 (1.92 to 5.50)	<0.001
Age ≥ 60 years				
<120/80	319	29	Reference	
120-129/<80	193	22	1.28 (0.74 to 2.24)	0.38
130-139/80-89	489	62	1.47 (0.94 to 2.29)	0.09
140-159/90-99	421	46	1.16 (0.72 to 1.85)	0.55
$\geq 160/100$	360	47	1.41 (0.88 to 2.26)	0.16

according to baseline blood pressure levels

CVDs: cardiovascular diseases; HR: hazard ratio; CI: confidence interval

Discussion

The present 20-year prospective study filled the gaps for implying the generalizability of the 2017 ACC/AHA Hypertension Guideline to rural Chinese populations. The results showed there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA and CVDs mortality when compared with SBP/DBP of <120/80. In addition, we detected high blood pressure was associated with higher mortality from CVDs among people aged 35-59 years rather than those aged 60 years and over. The findings may contribute to the optimal management of hypertension to address the growing burden of CVDs morbidity and mortality among rural Chinese populations, suggesting a large implication both to clinicians and public health practitioners.

In clinical practice, the staging of hypertension defined by SBP and DBP corresponds with the graded increased risk of cardiovascular disease and events and is in relation with pathophysiological mechanisms, prognostic implications, and therapeutic approaches [14-16]. For example, initiation of pharmacological therapy is recommended for adults with stage 2 hypertension [16]. ACC/AHA Task Force on Clinical Practice Guidelines released the 2017 hypertension guideline, which defined a SBP of 130 to 139 mm Hg or DBP of 80 to 89 mm Hg as stage 1 hypertension supported by the evidence from SPRINT [6,8]. Based on the new criterion, the prevalence of hypertension would increase substantially in many countries [17-19]. Although intensive blood pressure control was beneficial to cardiovascular events and total mortality, it was associated with an increased number of newly diagnosed hypertensive

1
2
3
4 patients who may not develop CVD events in the future [17]. In particular, with a large aging
5
6 population, there was a high prevalence of hypertension in China [20-22]. Besides, it is
7
8 estimated that 2.33 million cardiovascular deaths were attributable to increased blood
9
10 pressure in China [23]. Furthermore, contrary to western countries that CVD mortality has
11
12 decreased significantly during the past years, CVD mortality has increased during the same
13
14 period in China [3,24]. Thus, whether the results of SPRINT apply to rural Chinese
15
16 populations is a critical question to answer among Chinese populations.
17
18
19
20
21
22
23
24

25 In the current study, we firstly examined the association between hypertension of $\geq 140/90$
26
27 mm Hg and mortality from CVDs. The result showed a higher risk of mortality from CVDs
28
29 in hypertensive patients when compared with non-hypertensive participants (HR=1.35),
30
31 which was comparable with previous studies [4,23-25].
32
33
34
35
36
37

38 In the analysis by different blood pressure levels at baseline, the HR of CVDs mortality
39
40 related to stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline (130-
41
42 139/80-89 mm Hg) was not statistically higher than that related to SBP/DBP of $<120/<80$ mm
43
44 Hg in our study. Previous studies have demonstrated diagnosed hypertensive patients tended
45
46 to prescribe antihypertensive medications despite the lifestyle modifications management
47
48 suggestions [18,26], which may increase adverse effects caused by anti-hypertension
49
50 treatment among the newly diagnosed patients such as acute kidney injury, acute renal failure,
51
52 hypotension, syncope, or electrolyte abnormality [13,27]. In addition, the higher hypertension
53
54 diagnosis costs due to treatment is another important issue [27,28]. Since there was a lack of
55
56
57
58
59
60

1
2
3
4 awareness, adherence to hypertension guidelines, as well as access to antihypertensive drugs
5
6 in China, the health and cost-effectiveness of the new diagnostic criteria for hypertension
7
8 should be evaluated further. Thus, the results in our study may help address the current
9
10 evidence gaps about whether the 2017 ACC/AHA guideline could be applied to populations
11
12 in rural China.
13
14
15

16
17
18
19 Further, the stratified analysis according to age groups showed that the associations between
20
21 hypertension and CVDs mortality were stronger among participants aged 35-59 years than
22
23 those aged 60 years and above. A previous study also showed the association was significant
24
25 in the age groups of 35 to 44 and 45 to 59 years rather than in the group of ≥ 60 years [12].
26
27 Besides, a study based on pooling data from 7 diverse US cohort studies showed that
28
29 individuals who experienced blood pressure increases prior to middle age have associated
30
31 higher remaining lifetime risk for CVDs when compared with those who had developed
32
33 hypertension later in age 55 [29]. Similarly, a previous meta-analysis of 13 prospective cohort
34
35 studies involving 396,200 participants showed that pre-hypertension was not associated with
36
37 CVDs risk among older populations with age ≥ 60 years [30]. It is reported that the
38
39 cardiovascular risk for hypertensive patients decreased as age of onset increased from 40 to
40
41 69 years [31]. Possible explanations for the age-specific association between hypertension
42
43 and mortality from CVDs needs further studies to explore. In addition, it is important to
44
45 consider the influence of age in the diagnosis of hypertension.
46
47
48
49
50
51
52
53
54

55
56
57
58 The 20-year prospective study included a relatively large sample size examining the
59
60

1
2
3
4 association between high blood pressure and mortality from CVDs in rural China. The CVDs
5
6 deaths in the current study were comparable with several previous studies in China [13,32].
7
8
9 A previous study suggested a north-south gradient in the mortality of CVDs due to the
10
11 difference in prevalence of hypertension in China [33]. Furthermore, the Sino-MONICA
12
13 study showed that the number of deaths caused by stroke was larger than that caused by
14
15 coronary heart disease [34]. In addition, 73% of the stroke burden could be attributed to
16
17 hypertension in China, and prevalence of hypertension in stroke survivors in China was
18
19 relatively high when compared with other countries [35]. Besides, most of the stroke deaths
20
21 (64.3%) were attributable to ischemic stroke in the current study. Previous studies indicate
22
23 that atrial fibrillation is the most common cause of ischemic stroke and an increased risk of
24
25 stroke was observed in hypertensive patients with atrial fibrillation [36-39], which may be
26
27 another reason for the larger number of stroke deaths compared with coronary heart disease.
28
29 Further studies are needed to explore the role of atrial fibrillation in the association between
30
31 hypertension and stroke mortality to confirm our findings. Fangshan District is located in the
32
33 "stroke belt" of China [40]. Thus, the study is important to elucidate the association between
34
35 stage 1 hypertension defined by the 2017 ACC/AHA Hypertension Guideline and
36
37 cardiovascular deaths in rural China.
38
39
40
41
42
43
44
45
46
47
48
49

50 Nevertheless, the study has several limitations. Firstly, we cannot exclude the influence of
51
52 some potential confounding factors despite we conducted the analysis with careful adjustment.
53
54 In particular, the definition of smoking, alcohol consumption, salt intake, and the use of
55
56 antihypertensive drugs was relative simple due to limited information in the baseline
57
58
59
60

1
2
3
4 questionnaire. Secondly, hypertension was defined by SBP/DBP at baseline while we failed
5
6 to acquire blood pressure measurements during follow-up, which may underestimate the
7
8 strength of the associations we observed. Next, we had insufficient sample size to explore
9
10 whether the effects of hypertension on CVDs mortality differ by baseline comorbidities
11
12 including diabetes or chronic kidney disease. In addition, information of death was obtained
13
14 from the Death Surveillance System, the participants lost to follow-up were hard to detect
15
16 and may cause potential bias. Therefore, further studies with a larger sample size are needed
17
18 to validate the results in the study. More importantly, our study only included participants in
19
20 rural China, which might limit the generalizability of the results to other populations with
21
22 different socioeconomic status, environmental exposures, or genetic background.
23
24
25
26
27
28
29
30
31

32 **Conclusion**

33
34
35 In conclusion, the current study revealed hypertension of $\geq 140/90$ mm Hg was an important
36
37 risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage
38
39 1 hypertension under the definition of 2017 ACC/AHA was not associated with increased risk
40
41 of CVDs mortality. This study indicated that whether adopting the new hypertension
42
43 definition needs further consideration among rural Chinese populations.
44
45
46
47
48
49

50 **Competing interests**

51
52
53 The authors declare that they have no competing interests.
54
55
56
57

58 **Funding**

1
2
3
4 This work was supported by the Key Project of Natural Science Funds of China (81230066)
5
6 and National Natural Science Foundation of China (81473043, 81502874, 81573226,
7
8 81703291).

14 **Contributorship statement**

16 MW, TW, and YH conceived and designed the paper. LL, WC, JL, YW, XQ, XT, QZ, SH, SZ,
17
18 YH, TW, and DY coordinated the data acquisition and contributed to critical revision of the
19
20 manuscript for important intellectual content. MW, PG, WG, and CY analyzed the data. MW
21
22 and TW drafted the manuscript. MW, TW, LL, and YH and were responsible for the overall
23
24 content of article and data analysis. The manuscript is approved by all authors for publication.
25
26
27
28
29
30
31

32 **Data availability statement**

33 All data relevant to the study are included in the article.
34
35
36
37
38
39

40 **References**

- 41
42
43 1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of
44
45 Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.
46
47 *JAMA* 2017;317:165-182.
- 48
49
50 2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global
51
52 Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-
53
54 Based Studies From 90 Countries. *Circulation* 2016;134:441-50.
- 55
56
57 3. Lewington S, Lacey B, Clarke R, Guo Y, Kong XL, Yang L, et al. The Burden of
58
59
60

- 1
2
3
4 Hypertension and Associated Risk for Cardiovascular Mortality in China. *JAMA Intern*
5
6 *Med* 2016;176:524-32.
7
8
- 9 4. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering
10
11 treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet*
12
13 2014;384:591-598.
14
15
- 16 5. Angell SY, De Cock KM, Frieden TR. A public health approach to global management of
17
18 hypertension. *Lancet* 2015;385:825-7.
19
20
21
- 22 6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C,
23
24 et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
25
26 guideline for the prevention, detection, evaluation, and management of high blood pressure
27
28 in adults: a report of the American College of Cardiology/American Heart Association
29
30 Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;71:e127-e248.
31
32
33
34
- 35 7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018
36
37 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*
38
39 2018;39:3021-3104.
40
41
42
- 43 8. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure
44
45 control. *N Engl J Med* 2015;373:2103-2116.
46
47
- 48 9. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic Blood Pressure
49
50 Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and
51
52 Network Meta-analysis. *JAMA Cardiol* 2017;2:775-781.
53
54
55
- 56 10. Kulenthiran S, Ewen S, Böhm M, Mahfoud F. Hypertension up to date: SPRINT to
57
58 SPYRAL. *Clin Res Cardiol* 2017;106:475-484.
59
60

- 1
2
3
4 11. Sun X, Guo Y, Nie Z, Cheng J, Zhou H, Zhong X, et al. Influence of baseline systolic blood
5
6 pressure on the relationship between intensive blood pressure control and cardiovascular
7
8 outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT). *Clin Res Cardiol*
9
10 2019;108:273-281.
11
12
- 13
14 12. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive
15
16 Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *N Engl J Med*
17
18 2016;375:1033-43.
19
20
- 21
22 13. Qi Y, Han X, Zhao D, Wang W, Wang M, Sun J, et al. Long-Term Cardiovascular Risk
23
24 Associated With Stage 1 Hypertension Defined by the 2017 ACC/AHA Hypertension
25
26 Guideline. *J Am Coll Cardiol* 2018;72:1201-1210.
27
28
- 29
30 14. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al.
31
32 Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-
33
34 years lost, and age-specific associations in 1.25 million people. *Lancet* 2014;383:1899-911.
35
36
- 37
38 15. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their
39
40 course and prognosis. *Am J Med Sci* 1974;268:336-45.
41
42
- 43
44 16. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C,
45
46 et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
47
48 guideline for the prevention, detection, evaluation, and management of high blood pressure
49
50 in adults: a report of the American College of Cardiology/American Heart Association
51
52 Task Force on clinical practice guidelines. *Hypertension* 2018;71:1269-1324.
53
54
- 55
56 17. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the Association of the
57
58 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US
59
60

- 1
2
3
4 Adults: An Analysis of National Data. *JAMA Cardiol* 2018;3:572-581.
5
6
7 18. Dorans KS, Mills KT, Liu Y, He J. Trends in Prevalence and Control of Hypertension
8
9 According to the 2017 American College of Cardiology/American Heart Association
10
11 (ACC/AHA) Guideline. *J Am Heart Assoc* 2018;7. pii: e008888.
12
13
14 19. Kibria GMA, Swasey K, Choudhury A, Burrowes V, Stafford KA, Uddin SMI, et al. The
15
16 new 2017 ACC/AHA guideline for classification of hypertension: changes in prevalence
17
18 of hypertension among adults in Bangladesh. *J Hum Hypertens* 2018;32:608-616.
19
20
21 20. National Bureau of Statistics of the People's Republic of China. The Sixth National
22
23 Population Census of the People's Republic of China. 2010. Available at:
24
25 <http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/in>. Accessed December 5, 2018.
26
27
28 21. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment,
29
30 and control of hypertension in China: data from 1.7 million adults in a population-based
31
32 screening study (China PEACE Million Persons Project). *Lancet* 2017;390:2549-58.
33
34
35 22. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in
36
37 China: results from the China Hypertension Survey, 2012-2015. *Circulation*
38
39 2018;137:2344-56.
40
41
42 23. He J, Gu D, Chen J, Wu X, Kelly TN, Huang J, et al. Premature deaths attributable to blood
43
44 pressure in China: a prospective cohort study. *Lancet* 2009;374:1765-72.
45
46
47 24. Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, et al. Cause-specific mortality for 240
48
49 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden
50
51 of Disease Study 2013. *Lancet* 2016;387:251-72.
52
53
54 25. Bundy JD, He J. Hypertension and related cardiovascular disease burden in China. *Ann*
55
56
57
58
59
60

- 1
2
3
4 *Glob Health* 2016;82:227-33.
- 5
6
7 26. Wang JG, Liu L. Global Impact of 2017 American College of Cardiology/American Heart
8 Association Hypertension Guidelines: A Perspective From China. *Circulation*
9 2018;137:546-548.
- 10
11
12
13
14 27. Bakris G, Sorrentino M. Redefining Hypertension-Assessing the New Blood-Pressure
15 Guidelines. *N Engl J Med* 2018;378:497-499.
- 16
17
18
19 28. Gijón-Conde T, Sánchez-Martínez M, Graciani A, Cruz JJ, López-García E, Ortolá R, et
20 al. Impact of the European and American guidelines on hypertension prevalence, treatment,
21 and cardiometabolic goals. *J Hypertens* 2019;37:1393-1400.
- 22
23
24
25
26
27 29. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood
28 pressure and blood pressure change during middle age on the remaining lifetime risk for
29 cardiovascular disease: the cardiovascular lifetime risk pooling project. *Circulation*
30 2012;125:37-44.
- 31
32
33
34
35
36
37 30. Wang S, Wu H, Zhang Q, Xu J, Fan Y. Impact of baseline prehypertension on
38 cardiovascular events and all-cause mortality in the general population: a meta-analysis of
39 prospective cohort studies. *Int J Cardiol* 2013;168:4857-60.
- 40
41
42
43
44
45
46 31. Buck C, Baker P, Bass M, Donner A. The prognosis of hypertension according to age at
47 onset. *Hypertension* 1987;9:204-208.
- 48
49
50
51 32. Zhu N, Yu C, Guo Y, Bian Z, Han Y, Yang L, et al; China Kadoorie Biobank Collaborative
52 Group. Adherence to a healthy lifestyle and all-cause and cause-specific mortality in
53 Chinese adults: a 10-year prospective study of 0.5 million people. *Int J Behav Nutr Phys*
54 *Act* 2019;16:98.
- 55
56
57
58
59
60

- 1
2
3
4 33. Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J, et al. Epidemiological transition of stroke
5
6 in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project.
7
8 *Stroke* 2008;39:1668-74.
9
10
11 34. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA Project: a collaborative
12
13 study on trends and determinants in cardiovascular diseases in China, part I: morbidity and
14
15 mortality monitoring. *Circulation* 2001;103:462-8.
16
17
18 35. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, Incidence, and Mortality
19
20 of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults.
21
22 *Circulation* 2017;135:759-771.
23
24
25 36. Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk factor management
26
27 in atrial fibrillation. *Arrhythm Electrophysiol Rev* 2018;7:118-27.
28
29
30 37. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ. Validation of
31
32 clinical classification schemes for predicting stroke: results from the national registry of
33
34 atrial fibrillation. *JAMA* 2001;285:2864-2870.
35
36
37 38. Tohgi H, Tajima T, Konno T, Towada S, Kamata A, Yamazaki M. The risk of cerebral
38
39 infarction in non-valvular atrial fibrillation: effects of age, hypertension and
40
41 antihypertensive treatment. *Eur Neurol* 1991;31:126-130.
42
43
44 39. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for
45
46 stroke: the Framingham study. *Stroke* 1991;22:983-988.
47
48
49 40. Tang X, Hu Y, Chen D, Zhan S, Zhang Z, Dou H. The Fangshan/Family-based Ischemic
50
51 Stroke Study In China (FISSIC) protocol. *BMC Med Genet* 2007;8:60.
52
53
54
55
56
57
58
59
60

Supplementary Table 1 Multivariable hazard ratios (HRs) of all-cause, coronary heart disease, and stroke mortality according to baseline history of hypertension

Cause of mortality	N	Deaths	Adjusted HR (95% CI)	<i>P</i>
All-cause				
Baseline hypertension status				
No	5118	358	Reference	
Yes	2196	251	1.18 (0.99 to 1.40)	0.06
Coronary heart disease				
Baseline hypertension status				
No	5118	59	Reference	
Yes	2196	54	1.40 (0.95 to 2.07)	0.09
Stroke				
Baseline hypertension status				
No	5118	76	Reference	
Yes	2196	72	1.58 (1.12 to 2.22)	0.009

HR: hazard ratio; CI: confidence interval

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	<p>(a) Page 1, page 2, and page 3. The study was a prospective cohort study, which was conducted to explore the association between blood pressure and cardiovascular diseases mortality.</p> <p>The title was: The association between blood pressure levels and cardiovascular deaths: a 20-year follow-up study in rural China.</p> <p>(b) Page 2 and page 3. The abstract gave a brief introduction of the objectives, methods, results, and conclusions of the study.</p>
Introduction		
Background/rationale	2	Page 5 and page 6. In the introduction section, we demonstrated that the optimal blood pressure, particularly for systolic blood pressure (SBP) treatment target is unclear worldwide. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults recommended 130/80 mmHg as blood pressure target goals. However, the generalizability of SPRINT findings to populations at large with hypertension remains controversial.
Objectives	3	Page 6. We aimed to assess the relative risk of CVDs mortality associated with different stages of hypertension according to 2017 ACC/AHA using a 20-year follow-up study in China, to further evaluate the generalizability of SPRINT findings and explore the target blood pressure levels among Chinese populations.
Methods		
Study design	4	Page 6. As stated it in the Methods section, our study was a prospective cohort study.
Setting	5	Page 6. The study was a community-based follow-up study for the prevention and treatment of hypertension, which is being conducted in Fangshan District, Beijing, China.
Participants	6	Page 6 and page 7. As described in the Methods section about the participants, from January 1997 through June 1999, 8,189 participants aged 35 to 97 years were enrolled. Informed consent was obtained from all participants. In addition, the study was approved by the Institutional Review Board of Peking University Health Science Center.
Variables	7	<p>Page 7.</p> <p>The primary outcome variable was death from CVDs. The information of death was continuously obtained from the Death Surveillance System in the Center for Disease Prevention and Control in Fangshan District. Date of death was ascertained from the record in the system. We determined survival times from the date participants investigated in the baseline survey through December 31, 2017. Participants who were alive at the end of this period contributed with censored observations to the survival analyses of time to death. The causes of death were coded using the International Classification of Diseases, Ninth Revision (ICD-9) codes from 1997 to 2001, and International Classification of Diseases, Tenth Revision (ICD-10) codes from 2002-2017.</p>
Data sources/ measurement	8*	The primary exposure variables for these analyses included age at the enrollment and the blood pressure level at baseline. Data on sociodemographic characteristics,

lifestyles, and medical history of the participants were collected through questionnaire interview by trained staff members.

Participants were defined as never smokers, former smokers, and current smokers. Information on alcohol consumption was obtained through asking the participants to describe their drinking status: never, light (less than 2 drinks a day), or heavy (≥ 2 drinks a day). Further, the salt intake of the participants was assessed according to the question of what kind of taste they liked (salty taste, moderate, or light taste).

Physical measurements included height, weight, and blood pressure. Blood pressure levels were measured 3 times using a mercury sphygmomanometer by trained investigators. The mean of the 3 recorded measurements were included in the analysis. Hypertension was defined as SBP ≥ 140 mm Hg, systolic blood pressure (DBP) ≥ 90 mm Hg, self-reported antihypertensive medication in the past 2 weeks, or self-reported history of hypertension.

Bias	9	Page 8 and page 9. Potential bias may exist despite careful adjustment for potential confounders in the analysis.
Study size	10	Page 6 and page 7. A total of 7,314 participants (3,346 males and 3,968 females) were included in the analysis.
Quantitative variables	11	Page 9. Age and BMI were handled as quantitative variables in the models.
Statistical methods	12	(a) Page 8 and page 9. Student's t-test and Chi-square test were used to test the differences between different baseline hypertensive history groups for continuous variables and categorical variables, respectively. Person-years for each participant were calculated as the duration from the survey date at baseline through death date or date of lost to follow-up, whichever came first. The Cox proportional hazards regression model for CVDs death included baseline blood pressure level, age, sex, education level, body mass index, smoking status, alcohol use, dietary salt intake, antihypertensive medications, and family history of hypertension. Participants were classified as two groups according to baseline hypertensive status, and non-hypertension ($<140/90$ mmHg) was treated as reference. (b) Page 9. To test for possible interactions between age and hypertension, we categorized age with cutoffs of 60 years and hypertension as binary variables, and setting variable cross-product terms of hypertension (yes/no) with age (<60 and ≥ 60 years) in the model. Reference groups were SBP/DBP of less than 140/90 mm Hg and age of less than 60 years. We also performed a subgroup analysis according to baseline blood pressure levels (SBP/DBP: $<120/<80$, 120 to 129/ <80 , 130 to 139/80 to 89, 140 to 159/90 to 99, and $\geq 160/\geq 100$ mm Hg), where SBP/DBP of $<120/<80$ was treated as the reference group. (c) There was no missing data in the analysis since standard quality control criteria were adopted in our study. (d) Not applicable (e) We did not conduct any sensitivity analyses

Continued

on

next

page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Participants	13*	(a) Page 6 and page 7. Our study only had one stage, and all 7,314 participants were included in the analysis. (b) Not applicable (c) Not applicable
Descriptive data	14*	(a) Page 9 and page 10. Of the 7,314 participants (aged 50.65±11.8 years), the prevalence of hypertension was 30.02%. The proportion of people aged 60 years and above was higher in hypertensive patients (36.75%) when compared with non-hypertensive participants (19.05%, P<0.001). In addition, hypertensive patients were less educated than non-hypertensive participants (P<0.001). Moreover, there were more participants with tobacco smoking (49.27% vs. 44.92%) and alcohol consumption (31.74% vs. 30.15%) among hypertensive patients when compared with non-hypertensive participants. Furthermore, the percentage of obesity was higher among hypertensive patients when compared with non-hypertensive participants (P<0.001). (b) Not applicable
Outcome data	15*	Page 11. During the median follow-up of 20 years, we identified 350 deaths from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs).
Main results	16	(a) Page 11 and page 12. We detected statistically significant association between hypertension and the risk of mortality from CVDs (HR=1.35; 95% CI, 1.08 to 1.69). In the subgroup analysis based on baseline age, we found that, for people aged 35-59 years, hypertensive patients had a higher risk of mortality from CVDs when compared to those without hypertension (HR=2.49; 95% CI, 1.77 to 3.50). (b) Page 11 and page 12. There was no significant association between hypertension and the risk of mortality due to CVDs among people aged 60 years and over (P>0.05). Thus, age may significantly modify the association between hypertension and risk of mortality from CVDs (P for interaction<0.001). (c) Not applicable
Other analyses	17	Page 12 and page 13. Hypertensive patients with SBP/DBP of 140-159/90-99 and ≥160/100 mm Hg were more likely to die of CVDs (HR=1.44; 95% CI, 1.02 to 2.03; HR=1.74; 95% CI, 1.22 to 2.48) when compared with participants with SBP/DBP of <120/80 mm Hg. However, we failed to detect significant associations between SBP/DBP of 130-139/80-89 mm Hg (HR=1.18; 95% CI, 0.85 to 1.64, P=0.32) and 120-129/<80 mm Hg (HR=1.38; 95% CI, 0.93 to 2.05, P=0.11) and the risk of mortality from CVDs, respectively. Further, among participants aged<60 years at baseline, similar trend was observed between hypertension and the risk of mortality due to CVDs, where HR was 2.32 (P<0.001) for SBP/DBP of 140-159/90-99 mm Hg and 3.25 (P<0.001) for ≥160/100 mm Hg, respectively. However, there was no significant association between hypertension and the risk of mortality from CVDs with different baseline blood pressure levels for those aged≥60 years (P for interaction<0.001).

Discussion

Key results	18	Page 14, page 15, and page 16. The present 20-year prospective study filled the gaps for implying the generalizability of the 2017 ACC/AHA Hypertension Guideline to Chinese populations. The results showed there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA and CVDs mortality when compared with SBP/DBP of <120/80. In addition, we detected high blood pressure was associated with higher mortality from CVDs among people aged 35-59 years rather than those aged 60 years and over. The findings may contribute to the optimal management of hypertension to address the
-------------	----	---

growing burden of CVDs morbidity and mortality in China, suggesting a large implication both to clinicians and public health practitioners.

Limitations	19	Page 17 and page 18. Nevertheless, the study has several limitations. Firstly, we cannot exclude the influence of some potential confounding factors despite we conducted the analysis with careful adjustment. In particular, the definition of smoking, alcohol consumption, salt intake, and the use of antihypertensive drugs was relative simple due to limited information in the baseline questionnaire. Secondly, hypertension was defined by SBP/DBP at baseline while we failed to acquire blood pressure measurements during follow-up, which may underestimate the strength of the associations we observed. Next, we had insufficient sample size to explore whether the effects of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or chronic kidney disease. In addition, information of death was obtained from the Death Surveillance System, the participants lost to follow-up were hard to detect and may cause potential bias. Therefore, further studies with a larger sample size are needed to validate the results in the study. More importantly, our study only included participants in rural China, which might limit the generalizability of the results to other populations with different socioeconomic status, environmental exposures, or genetic background.
Interpretation	20	Page 14, page 15, and page 16. From an objective perspective, we discussed the results from the aspects recommended in the STROBE Checklist.
Generalisability	21	Page 18. The current study revealed hypertension of $\geq 140/90$ mm Hg was an important risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage 1 hypertension under the definition of 2017 ACC/AHA was not associated with increased risk of CVDs mortality. This study indicated that whether adopting the new hypertension definition needs further consideration in rural China.

Other information

Funding 22 Page 18. All sources of funding were described in the Acknowledgement section.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

The association between blood pressure levels and cardiovascular deaths: a 20-year follow-up study in rural China

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035190.R2
Article Type:	Original research
Date Submitted by the Author:	20-Jan-2020
Complete List of Authors:	Wang, Mengying; Peking University, Epidemiology and Biostatistics Wu, Tao; Peking University, Epidemiology and Biostatistics Yu, Canqing; Peking University, Epidemiology and Biostatistics Gao, Wenjing; Peking University, Epidemiology and Biostatistics Lv, Jun; Peking University, Epidemiology and Biostatistics Wu, Yiqun; Peking University, Epidemiology and Biostatistics Qin, Xueying; Peking University, Epidemiology and Biostatistics TANG, Xun; Peking University, Epidemiology and Biostatistics Gao, Pei; Peking University, Epidemiology and Biostatistics Zhan, Siyan; Peking University, Epidemiology and Biostatistics Cao, Weihua; Peking University, Epidemiology and Biostatistics Zhao, Qingshui; General Office Huang, Shaoping; General Office Yang, Dongli; General Office LI, Li-ming; Peking University, Epidemiology and Biostatistics Hu, Yong-Hua; Peking University, Epidemiology and Biostatistics
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Evidence based practice
Keywords:	Hypertension < CARDIOLOGY, Stroke < NEUROLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The association between blood pressure levels and cardiovascular deaths: a 20-year follow-up
study in rural China

Mengying Wang¹, Tao Wu^{1*}, Canqing Yu¹, Wenjing Gao¹, Jun Lv¹, Yiqun Wu¹, Xueying
Qin¹, Xun Tang¹, Pei Gao¹, Siyan Zhan¹, Weihua Cao¹, Qingshui Zhao², Shaoping Huang²,
Dongli Yang³, Liming Li¹, Yonghua Hu¹

E-mail address for authors

Mengying Wang: 1461589478@qq.com; Tao Wu: twu@bjmu.edu.cn;

Canqing Yu: yucanqing@pku.edu.cn; Wenjing Gao: pkugwj@qq.com;

Jun Lv: lvjun@bjmu.edu.cn; Yiqun Wu: qywu118@163.com;

Xueying Qin: xueyingqin@bjmu.edu.cn; Xun Tang: tangxun@bjmu.edu.cn;

Pei Gao: pei_gao@163.com; Siyan Zhan: siyan-zhan@bjmu.edu.cn;

Weihua Cao: caoweihua60@163.com; Qingshui Zhao: zqs_67189@163.com;

Shaoping Huang: 2146733477@qq.com; Dongli Yang: 2178757723@qq.com;

Liming Li: lmlee@vip.163.com; Yonghua Hu: yhhu@bjmu.edu.cn

¹Department of Epidemiology and Biostatistics, School of Public Health, Peking University

² Department of General Office, Fangshan District Center for Disease Control and Prevention,
Beijing, China

³ Department of General Office, Fangshan District Health Commission, Beijing, China

Corresponding to:

Tao Wu, Department of Epidemiology and Biostatistics, School of Public Health, Peking
University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing, China, 100191.

E-mail: twu@bjmu.edu.cn

Abstract

Objectives: The 2017 ACC/AHA Hypertension Guideline recommended 130/80 mmHg as blood pressure (BP) target goals. However, the generalizability of this recommendation to populations at large with hypertension remains controversial. We assessed the association between BP and cardiovascular diseases (CVDs) mortality using a 20-year follow-up study among Chinese populations.

Design: Prospective cohort study.

Participants: 7,314 participants were followed up for a median of 20 years in Fangshan District, Beijing, China.

Methods: The primary outcome variable was death from cardiovascular causes. The adjusted hazard ratio (HR) for CVDs mortality associated with baseline BP was calculated using Cox regression analysis.

Results: We identified 350 deaths from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs) during follow-up. Hypertension (defined by systolic BP (SBP) /diastolic BP (DBP) $\geq 140/90$ mm Hg) was significantly associated with mortality due to CVDs (HR=2.49, 95% CI=1.77-3.50) among people aged 35-59 years rather than people aged ≥ 60 . In addition, there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA (SBP/DBP of 130-139/80-89 mm Hg) and CVDs mortality when compared with SBP/DBP of $<120/80$ in neither the participants aged <60 years (HR=0.90, 95% CI=0.54-1.50) nor participants aged ≥ 60 years (HR=1.47, 95% CI=0.94-2.29).

Conclusion: The study revealed hypertension of SBP/DBP $\geq 140/90$ mm Hg was an important risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage

1
2
3
4 1 hypertension under the definition of 2017 ACC/AHA was not associated with an increased
5
6 risk of CVDs mortality. This study indicated that whether adopting the new hypertension
7
8 definition needs further consideration in rural Chinese populations.
9
10

11 **Keywords:** hypertension; mortality; cardiovascular diseases; cohort study
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

1. The prospective study had a relatively long follow-up time of 20 years.
2. The study examined the association between high blood pressure and mortality from CVDs, which were hard outcomes.
3. Hypertension was defined by systolic blood pressure or diastolic blood pressure at baseline while we failed to acquire blood pressure measurements during follow-up, which may underestimate the strength of the associations we observed.
4. Whether the effects of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or chronic kidney disease was not explored due to limited data.
5. The information of death was obtained from the Death Surveillance System, the participants lost to follow-up were hard to detect and may cause potential bias.

Introduction

Hypertension is the first risk factor of cardiovascular diseases (CVDs), accounted for 7.8 million deaths and 148 million disability life years lost worldwide in 2015 [1]. It has been reported that hypertension affected nearly 30% of the adult population in Western countries as well as in China [2,3].

The management of high blood pressure is a public health priority with implications for the prevention of CVDs [4,5]. However, the optimal blood pressure, particularly for systolic blood pressure (SBP) treatment target is unclear worldwide. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommended 130/80 mmHg as blood pressure target goals [6]. However, the definition of hypertension remains $\geq 140/90$ mm Hg in the European guideline [7].

The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated intensive SBP lowering in adults without diabetes or stroke could result in significant decreases in cardiovascular events and all-cause mortality [8]. A network meta-analysis conducted by Bundy et al also suggested that a more intensive treatment target (eg, SBP of 120-124 mm Hg) showed improvement in the prevention of CVD complications and total mortality when compared with a standard SBP target (<140 mm Hg) [9]. However, the generalizability of SPRINT findings to populations at large with hypertension remains controversial [9-13]. For example, a recent study showed that the treatment to achieve a target SBP of 110 to 139 mm

1
2
3
4 Hg did not result in a lower rate of death than standard reduction to a target of 140 to 179
5
6 mmHg in hypertensive patients with intracerebral hemorrhage [12].
7
8
9

10
11 Here, we aimed to assess the relative risk of CVDs mortality associated with different stages
12
13 of hypertension according to 2017 ACC/AHA using a 20-year follow-up study in China, to
14
15 further evaluate the generalizability of SPRINT findings and explore the target blood pressure
16
17 levels among Chinese populations.
18
19
20
21
22

23 24 **Methods**

25 26 **Study design**

27
28 The participants for these analyses came from a community-based follow-up study for the
29
30 prevention and treatment of hypertension, which is being conducted in Fangshan District,
31
32 Beijing, China. Verbal informed consent was obtained from all participants. In addition, the
33
34 study was approved by the Institutional Review Board of Peking University Health Science
35
36 Center.
37
38
39
40
41
42
43
44
45

46 **Inclusion and exclusion of the participants**

47
48 From January 1997 through June 1999, 8,189 participants aged 35 to 97 years were enrolled.
49
50 We excluded 669 individuals with CVDs at baseline. In addition, we dropped the participants
51
52 if any of the key variables required in the analysis (blood pressure, height, weight,
53
54 demographic variables, or potential risk factors including smoking, alcohol consumption, or
55
56 high salt intake) were missing. Finally, a total of 7,314 participants (3,346 males and 3,968
57
58
59
60

1
2
3
4 females) were included in the analysis.
5
6
7
8

9 **Outcomes variables**

10
11 The primary outcome variable was death from CVDs. The information on death was
12 continuously obtained from the Death Surveillance System in the Center for Disease
13 Prevention and Control in Fangshan District. The date of death was ascertained from the
14 record in the system. We determined survival times from the date participants investigated in
15 the baseline survey through December 31, 2017. Participants who were alive at the end of
16 this period contributed with censored observations to the survival analyses of time to death.
17 The causes of death were coded using the International Classification of Diseases, Ninth
18 Revision (ICD-9) codes from 1997 to 2001, and International Classification of Diseases,
19 Tenth Revision (ICD-10) codes from 2002-2017.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37 **Data collection**

40 The primary exposure variables for these analyses included age at the enrollment and the
41 blood pressure level at baseline. Data on sociodemographic characteristics, lifestyles, and
42 medical history of the participants were collected by questionnaire interviews by trained staff
43 members.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

53 Participants were defined as never smokers, former smokers, and current smokers.
54 Information on alcohol consumption was obtained through asking the participants to describe
55 their drinking status: never, light (less than 2 drinks a day), or heavy (≥ 2 drinks a day). Further,
56
57
58
59
60

1
2
3
4 the salt intake of the participants was assessed according to the question of what kind of taste
5
6 they liked (salty taste, moderate, or light taste).
7
8
9

10
11 Physical measurements included height, weight, and blood pressure. Blood pressure levels were
12
13 measured 3 times using a mercury sphygmomanometer by trained investigators. The mean of
14
15 the 3 recorded measurements was included in the analysis.
16
17
18
19

20
21
22 Hypertension was defined as SBP \geq 140 mm Hg, diastolic blood pressure (DBP) \geq 90 mm Hg,
23
24 self-reported antihypertensive medication in the past 2 weeks, or a self-reported history of
25
26 hypertension [3]. In addition, according to the 2017 ACC/AHA guidelines, the participants
27
28 were divided into four categories: normal blood pressure (SBP < 120 mm Hg and DBP < 80 mm
29
30 Hg), elevated blood pressure (120 mm Hg \leq SBP \leq 129 mm Hg and DBP < 80 mm Hg), stage 1
31
32 hypertension (130 mm Hg \leq SBP \leq 139 mm Hg or 80 \leq DBP \leq 89 mm Hg), and stage 2
33
34 hypertension (SBP \geq 140 mm Hg/DBP \geq 90 mm Hg or taking antihypertensive medications).
35
36
37
38
39
40
41
42

43 **Statistical analysis**

44
45 Student's t-test and Chi-square tests were used to test the differences between different
46
47 baseline hypertensive history groups for continuous variables and categorical variables,
48
49 respectively.
50
51
52
53
54

55
56 Person-years for each participant were calculated as the duration from the survey date at
57
58 baseline through death date or date lost to follow-up, whichever came first. The Cox
59
60

1
2
3
4 proportional hazards regression model for CVDs death included baseline blood pressure level,
5
6 age, sex, education level, body mass index, smoking status, alcohol use, dietary salt intake,
7
8 antihypertensive medications, and family history of hypertension. Participants were classified
9
10 as two groups according to baseline hypertensive status, and non-hypertension (<140/90
11
12 mmHg) was treated as the reference. To test for possible interactions between age and
13
14 hypertension, we categorized age with cutoffs of 60 years and hypertension as binary
15
16 variables, and setting variable cross-product terms of hypertension (yes/no) with age (<60
17
18 and ≥ 60 years) in the model. Reference groups were SBP/DBP of less than 140/90 mm Hg
19
20 and age of less than 60 years. We also performed a subgroup analysis according to baseline
21
22 blood pressure levels (SBP/DBP: <120/<80, 120 to 129/<80, 130 to 139/80 to 89, 140 to
23
24 159/90 to 99, and $\geq 160/\geq 100$ mm Hg), where SBP/DBP of <120/<80 was treated as the
25
26 reference group.
27
28
29
30
31
32
33
34
35
36
37

38 All analyses were performed using R software (Version 3.5.1). All p-values for the tests were
39
40 two-sided and p-values<0.05 were considered as statistically significant.
41
42
43
44

45 Patient and public involvement

46
47 Patients or the public were not involved in the study.
48
49
50
51
52

53 Results

54
55 Of the 7,314 participants (aged 50.65 ± 11.8 years), the prevalence of hypertension was
56
57 30.02%. According to the 2017 ACC/AHA guideline, the prevalence of hypertension was
58
59
60

58.96%. The proportion of people aged 60 years and above was higher in hypertensive patients (36.75%) when compared with non-hypertensive participants (19.05%, $P<0.001$). In addition, hypertensive patients were less educated than non-hypertensive participants ($P<0.001$). Moreover, there were more participants with tobacco smoking (49.27% vs. 44.92%) and alcohol consumption (31.74% vs. 30.15%) among hypertensive patients when compared with non-hypertensive participants. Furthermore, the percentage of obesity was higher among hypertensive patients when compared with non-hypertensive participants ($P<0.001$) (Table 1).

Table 1 Characteristics of the participants by hypertensive status at baseline

	Hypertensive patients (n=2,196)	Non-hypertensive participants (n=5,118)	<i>P</i>
Age, n (%)			<0.001
<60	1,389 (63.25)	4,143 (80.95)	
≥60	807 (36.75)	975 (19.05)	
Sex, n (%)			<0.001
Male	1,002 (45.63)	2,344 (45.80)	
Female	1,194 (54.37)	2,774 (54.20)	
Education, n (%)			<0.001
Illiterate	805 (36.65)	1,224 (23.91)	
Primary	666 (30.33)	1,692 (33.06)	
Middle school	628 (28.60)	1,917 (37.46)	
High school and above	97 (4.42)	285 (5.57)	
Tobacco smoking, n (%)			<0.001
Non-smoking	1,114 (50.73)	2,819 (55.08)	
Ex-smoking	202 (9.20)	234 (4.57)	
Current smoking	880 (40.07)	2065 (40.35)	
Alcohol consumption, n (%)			<0.001
Non-drinking	1,499 (68.26)	3575 (69.85)	
Ex-drinking	510 (23.22)	1250 (24.42)	
Current drinking	187 (8.52)	293 (5.73)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMI (kg/m ²), n (%)			<0.001
BMI<18.5	48 (2.19)	91 (1.78)	
18.5≤BMI<23.9	956 (43.53)	2930 (57.25)	
24.0≤BMI<27.9	811 (36.93)	1752 (34.23)	
BMI≥28.0	381 (17.35)	345 (6.74)	

BMI: body mass index

During the median follow-up of 20 years, we have identified 609 deaths, of which 350 deaths were from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs). In the multivariable model adjusting for age, sex, educational level, smoking, alcohol consumption, dietary salt intake, body mass index (BMI), use of anti-hypertensive medications, and family history of hypertension, we detected statistically significant association between hypertension and mortality from CVDs (HR=1.35; 95% CI, 1.08 to 1.69). In the subgroup analysis based on baseline age, we found that, for people aged 35-59 years, hypertensive patients had a higher risk of mortality from CVDs when compared to those without hypertension (HR=2.49; 95% CI, 1.77 to 3.50) (Table 2). However, there was no significant association between hypertension and mortality due to CVDs among people aged 60 years and over ($P>0.05$) (Table 2). Thus, age may significantly modify the association between hypertension and mortality from CVDs (P for interaction<0.001). We also assessed the association between hypertension and all-cause, coronary heart disease, and stroke mortality (Supplementary Table 1).

Table 2 Multivariable hazard ratios (HRs) of mortality from cardiovascular diseases

	CVDs mortality			
	N	Deaths	Adjusted HR (95% CI)	P
Total				
Baseline hypertension status				
No	5118	189	Reference	
Yes	2196	161	1.35 (1.08 to 1.69)	0.01
Age < 60 years				
Baseline hypertension status				
No	4143	80	Reference	
Yes	1389	64	2.49 (1.77 to 3.50)	<0.001
Age ≥ 60 years				
Baseline hypertension status				
No	975	109	Reference	
Yes	807	97	1.01 (0.76 to 1.33)	0.96

according to baseline history of hypertension

CVDs: cardiovascular diseases; HR: hazard ratio; CI: confidence interval

Stratified analysis according to different baseline blood pressure showed that hypertensive patients with SBP/DBP of 140-159/90-99 and $\geq 160/100$ mm Hg were more likely to die of CVDs (HR=1.44; 95% CI, 1.02 to 2.03; HR=1.74; 95% CI, 1.22 to 2.48) when compared with participants with SBP/DBP of <120/80 mm Hg. However, we failed to detect significant associations between SBP/DBP of 130-139/80-89 mm Hg (HR=1.18; 95% CI, 0.85 to 1.64, $P=0.32$) and 120-129/<80 mm Hg (HR=1.38; 95% CI, 0.93 to 2.05, $P=0.11$) and mortality from CVDs, respectively. Further, among participants aged <60 years at baseline, a similar

trend was observed between hypertension and mortality due to CVDs, where HR was 2.32 ($P<0.001$) for SBP/DBP of 140-159/90-99 mm Hg and 3.25 ($P<0.001$) for $\geq 160/100$ mm Hg, respectively. However, there was no significant association between hypertension and mortality from CVDs with different baseline blood pressure levels for those aged ≥ 60 years (P for interaction <0.001) (Table 3).

Table 3 Multivariable hazard ratios (HRs) of mortality from cardiovascular diseases

	CVDs mortality			
	N	Deaths	Adjusted HR (95% CI)	<i>P</i>
Total				
<120/80	2132	61	Reference	
120-129/<80	920	43	1.38 (0.93 to 2.05)	0.11
130-139/80-89	2180	91	1.18 (0.85 to 1.64)	0.32
140-159/90-99	1239	80	1.44 (1.02 to 2.03)	0.04
$\geq 160/100$	843	75	1.74 (1.22 to 2.48)	<0.01
Age<60 years				
<120/80	1813	32	Reference	
120-129/<80	727	21	1.46 (0.84 to 2.55)	0.18
130-139/80-89	1691	29	0.90 (0.54 to 1.50)	0.70
140-159/90-99	818	34	2.31 (1.41 to 3.79)	<0.001
$\geq 160/100$	483	28	3.25 (1.92 to 5.50)	<0.001
Age ≥ 60 years				
<120/80	319	29	Reference	
120-129/<80	193	22	1.28 (0.74 to 2.24)	0.38
130-139/80-89	489	62	1.47 (0.94 to 2.29)	0.09
140-159/90-99	421	46	1.16 (0.72 to 1.85)	0.55
$\geq 160/100$	360	47	1.41 (0.88 to 2.26)	0.16

according to baseline blood pressure levels

CVDs: cardiovascular diseases; HR: hazard ratio; CI: confidence interval

Discussion

The present 20-year prospective study filled the gaps for implying the generalizability of the 2017 ACC/AHA Hypertension Guideline to rural Chinese populations. The results showed there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA and CVDs mortality when compared with SBP/DBP of <120/80. In addition, we detected high blood pressure was associated with higher mortality from CVDs among people aged 35-59 years rather than those aged 60 years and over. The findings may contribute to the optimal management of hypertension to address the growing burden of CVDs morbidity and mortality among rural Chinese populations, suggesting a large implication both to clinicians and public health practitioners.

In the current study, we firstly examined the association between hypertension of $\geq 140/90$ mm Hg and mortality from CVDs. The result showed a higher risk of mortality from CVDs in hypertensive patients when compared with non-hypertensive participants (HR=1.35), which was comparable with previous studies [4,14-16].

Further, the stratified analysis according to age groups showed that the associations between hypertension and CVDs mortality were stronger among participants aged 35-59 years than those aged 60 years and above. A previous study also showed the association was significant in the age groups of 35 to 44 and 45 to 59 years rather than in the group of ≥ 60 years [12].

Besides, a study based on pooling data from 7 diverse US cohort studies showed that

1
2
3
4 individuals who experienced blood pressure increases prior to middle age have associated
5
6 higher remaining lifetime risk for CVDs when compared with those who had developed
7
8 hypertension later in age 55 [17]. Similarly, a previous meta-analysis of 13 prospective cohort
9
10 studies involving 396,200 participants showed that pre-hypertension was not associated with
11
12 CVDs risk among older populations with age ≥ 60 years [18]. It is reported that the
13
14 cardiovascular risk for hypertensive patients decreased as the age of onset increased from 40
15
16 to 69 years [19]. Possible explanations for the age-specific association between hypertension
17
18 and mortality from CVDs needs further studies to explore. In addition, it is important to
19
20 consider the influence of age in the diagnosis of hypertension.
21
22
23
24
25
26
27
28
29

30 In clinical practice, the staging of hypertension defined by SBP and DBP corresponds with
31
32 the graded increased risk of cardiovascular disease and events and is in relation to
33
34 pathophysiological mechanisms, prognostic implications, and therapeutic approaches [20-22].
35
36 For example, the initiation of pharmacological therapy is recommended for adults with stage
37
38 2 hypertension [22]. ACC/AHA Task Force on Clinical Practice Guidelines released the 2017
39
40 hypertension guideline, which defined SBP of 130 to 139 mm Hg or DBP of 80 to 89 mm Hg
41
42 as stage 1 hypertension supported by the evidence from SPRINT [6,8]. Based on the new
43
44 criterion, the prevalence of hypertension would increase substantially in many countries [23-
45
46 25]. Although intensive blood pressure control was beneficial to cardiovascular events and
47
48 total mortality, it was associated with an increased number of newly diagnosed hypertensive
49
50 patients who may not develop CVD events in the future [23]. In particular, with a large aging
51
52 population, there was a high prevalence of hypertension in China [26-28]. It is estimated that
53
54
55
56
57
58
59
60

1
2
3
4 2.33 million cardiovascular deaths were attributable to increased blood pressure in China [14].
5
6 Furthermore, contrary to western countries that CVD mortality has decreased significantly
7
8 during the past years, CVD mortality has increased during the same period in China [3,15].
9
10 Thus, whether the results of SPRINT apply to rural Chinese populations is a critical question
11
12 to answer among Chinese populations.
13
14
15
16
17
18

19
20 In the current analysis by different blood pressure levels at baseline, the HR of CVDs
21
22 mortality related to stage 1 hypertension defined by the 2017 ACC/AHA hypertension
23
24 guideline (130-139/80-89 mm Hg) was not statistically higher than that related to SBP/DBP
25
26 of <120/<80 mm Hg. Previous studies have demonstrated diagnosed hypertensive patients
27
28 tended to prescribe antihypertensive medications despite the lifestyle modifications
29
30 management suggestions [18,29], which may increase adverse effects caused by anti-
31
32 hypertension treatment among the newly diagnosed patients such as acute kidney injury, acute
33
34 renal failure, hypotension, syncope, or electrolyte abnormality [13,30]. In addition, the higher
35
36 hypertension diagnosis costs due to treatment is another important issue [30,31]. Since there
37
38 was a lack of awareness, adherence to hypertension guidelines, as well as access to
39
40 antihypertensive drugs in China, the health and cost-effectiveness of the new diagnostic
41
42 criteria for hypertension should be evaluated further. The results in our study may help
43
44 address the current evidence gaps about whether the 2017 ACC/AHA guideline could be
45
46 applied to populations in rural China.
47
48
49
50
51
52
53
54
55
56
57

58 The 20-year prospective study included a relatively large sample size examining the
59
60

1
2
3
4 association between high blood pressure and mortality from CVDs in rural China. The CVDs
5
6 deaths in the current study were comparable with several previous studies in China [13,32].
7
8
9 A previous study suggested a north-south gradient in the mortality of CVDs due to the
10
11 difference in the prevalence of hypertension in China [33]. Furthermore, the Sino-MONICA
12
13 study showed that the number of deaths caused by stroke was larger than that caused by
14
15 coronary heart disease [34]. In addition, 73% of the stroke burden could be attributed to
16
17 hypertension in China, and the prevalence of hypertension in stroke survivors in China was
18
19 relatively high when compared with other countries [35]. Besides, most of the stroke deaths
20
21 (64.3%) were attributable to ischemic stroke in the current study. Previous studies indicate
22
23 that atrial fibrillation is the most common cause of ischemic stroke and an increased risk of
24
25 stroke was observed in hypertensive patients with atrial fibrillation [36-39], which may be
26
27 another reason for the larger number of stroke deaths compared with coronary heart disease.
28
29 Further studies are needed to explore the role of atrial fibrillation in the association between
30
31 hypertension and stroke mortality to confirm our findings. Fangshan District is located in the
32
33 "stroke belt" of China [40]. Thus, the study is important to elucidate the association between
34
35 stage 1 hypertension defined by the 2017 ACC/AHA Hypertension Guideline and
36
37 cardiovascular deaths in rural China.
38
39
40
41
42
43
44
45
46
47
48
49

50 **Limitations of the study**

51
52
53 Nevertheless, the study has several limitations. Firstly, we cannot exclude the influence of
54
55 some potential confounding factors despite we conducted the analysis with careful adjustment.
56
57
58 In particular, the definition of smoking, alcohol consumption, salt intake, and the use of
59
60

1
2
3
4 antihypertensive drugs was relatively simple due to limited information in the baseline
5
6 questionnaire. Secondly, hypertension was defined by SBP/DBP at baseline while we failed
7
8 to acquire blood pressure measurements during follow-up, which may underestimate the
9
10 strength of the associations we observed. Next, we had an insufficient sample size to explore
11
12 whether the effects of hypertension on CVDs mortality differ by baseline comorbidities
13
14 including diabetes or chronic kidney disease. In addition, information of death was obtained
15
16 from the Death Surveillance System, the participants lost to follow-up were hard to detect
17
18 and may cause potential bias. Therefore, further studies with a larger sample size are needed
19
20 to validate the results in the study. More importantly, our study only included participants in
21
22 rural China, which might limit the generalizability of the results to other populations with
23
24 different socioeconomic status, environmental exposures, or genetic background.
25
26
27
28
29
30
31
32
33
34

35 **Conclusion**

36
37 In conclusion, the current study revealed hypertension of $\geq 140/90$ mm Hg was an important
38
39 risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage
40
41 1 hypertension under the definition of 2017 ACC/AHA was not associated with an increased
42
43 risk of CVDs mortality. This study indicated that whether adopting the new hypertension
44
45 definition needs further consideration among rural Chinese populations.
46
47
48
49
50
51
52

53 **Competing interests**

54
55 The authors declare that they have no competing interests.
56
57
58
59
60

Funding

This work was supported by the Key Project of Natural Science Funds of China (81230066) and National Natural Science Foundation of China (81473043, 81502874, 81573226, 81703291).

Contributorship statement

MW, TW, and YH conceived and designed the paper. LL, WC, JL, YW, XQ, XT, QZ, SH, SZ, YH, TW, and DY coordinated the data acquisition and contributed to critical revision of the manuscript for important intellectual content. MW, PG, WG, and CY analyzed the data. MW and TW drafted the manuscript. MW, TW, LL, and YH and were responsible for the overall content of article and data analysis. The manuscript is approved by all authors for publication.

Data availability statement

All data relevant to the study are included in the article.

References

1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. *JAMA* 2017;317:165-182.
2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. *Circulation* 2016;134:441-50.

- 1
2
3
4 3. Lewington S, Lacey B, Clarke R, Guo Y, Kong XL, Yang L, et al. The Burden of
5
6 Hypertension and Associated Risk for Cardiovascular Mortality in China. *JAMA Intern*
7
8 *Med* 2016;176:524-32.
9
10
- 11 4. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering
12
13 treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet*
14
15 2014;384:591-598.
16
17
- 18 5. Angell SY, De Cock KM, Frieden TR. A public health approach to global management of
19
20 hypertension. *Lancet* 2015;385:825-7.
21
22
- 23 6. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C,
24
25 et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
26
27 guideline for the prevention, detection, evaluation, and management of high blood pressure
28
29 in adults: a report of the American College of Cardiology/American Heart Association
30
31 Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;71:e127-e248.
32
33
- 34 7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018
35
36 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*
37
38 2018;39:3021-3104.
39
40
- 41 8. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure
42
43 control. *N Engl J Med* 2015;373:2103-2116.
44
45
- 46 9. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic Blood Pressure
47
48 Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and
49
50 Network Meta-analysis. *JAMA Cardiol* 2017;2:775-781.
51
52
- 53 10. Kulenthiran S, Ewen S, Böhm M, Mahfoud F. Hypertension up to date: SPRINT to
54
55
56
57
58
59
60

- 1
2
3
4 SPYRAL. *Clin Res Cardiol* 2017;106:475-484.
5
6
7 11. Sun X, Guo Y, Nie Z, Cheng J, Zhou H, Zhong X, et al. Influence of baseline systolic blood
8
9 pressure on the relationship between intensive blood pressure control and cardiovascular
10
11 outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT). *Clin Res Cardiol*
12
13 2019;108:273-281.
14
15
16 12. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive
17
18 Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *N Engl J Med*
19
20 2016;375:1033-43.
21
22
23 13. Qi Y, Han X, Zhao D, Wang W, Wang M, Sun J, et al. Long-Term Cardiovascular Risk
24
25 Associated With Stage 1 Hypertension Defined by the 2017 ACC/AHA Hypertension
26
27 Guideline. *J Am Coll Cardiol* 2018;72:1201-1210.
28
29
30 14. He J, Gu D, Chen J, Wu X, Kelly TN, Huang J, et al. Premature deaths attributable to blood
31
32 pressure in China: a prospective cohort study. *Lancet* 2009;374:1765-72.
33
34
35 15. Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, et al. Cause-specific mortality for 240
36
37 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden
38
39 of Disease Study 2013. *Lancet* 2016;387:251-72.
40
41
42
43 16. Bundy JD, He J. Hypertension and related cardiovascular disease burden in China. *Ann*
44
45 *Glob Health* 2016;82:227-33.
46
47
48 17. Allen N, Berry JD, Ning H, Van Horn L, Dyer A, Lloyd-Jones DM. Impact of blood
49
50 pressure and blood pressure change during middle age on the remaining lifetime risk for
51
52 cardiovascular disease: the cardiovascular lifetime risk pooling project. *Circulation*
53
54 2012;125:37-44.
55
56
57
58
59
60

18. Wang S, Wu H, Zhang Q, Xu J, Fan Y. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies. *Int J Cardiol* 2013;168:4857-60.
19. Buck C, Baker P, Bass M, Donner A. The prognosis of hypertension according to age at onset. *Hypertension* 1987;9:204-208.
20. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet* 2014;383:1899-911.
21. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. *Am J Med Sci* 1974;268:336-45.
22. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. *Hypertension* 2018;71:1269-1324.
23. Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the Association of the 2017 and 2014 Hypertension Guidelines With Cardiovascular Events and Deaths in US Adults: An Analysis of National Data. *JAMA Cardiol* 2018;3:572-581.
24. Dorans KS, Mills KT, Liu Y, He J. Trends in Prevalence and Control of Hypertension According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline. *J Am Heart Assoc* 2018;7. pii: e008888.
25. Kibria GMA, Swasey K, Choudhury A, Burrowes V, Stafford KA, Uddin SMI, et al. The

- new 2017 ACC/AHA guideline for classification of hypertension: changes in prevalence of hypertension among adults in Bangladesh. *J Hum Hypertens* 2018;32:608-616.
26. National Bureau of Statistics of the People's Republic of China. The Sixth National Population Census of the People's Republic of China. 2010. Available at: <http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/in>. Accessed December 5, 2018.
27. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). *Lancet* 2017;390:2549-58.
28. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012-2015. *Circulation* 2018;137:2344-56.
29. Wang JG, Liu L. Global Impact of 2017 American College of Cardiology/American Heart Association Hypertension Guidelines: A Perspective From China. *Circulation* 2018;137:546-548.
30. Bakris G, Sorrentino M. Redefining Hypertension-Assessing the New Blood-Pressure Guidelines. *N Engl J Med* 2018;378:497-499.
31. Gijón-Conde T, Sánchez-Martínez M, Graciani A, Cruz JJ, López-García E, Ortolá R, et al. Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals. *J Hypertens* 2019;37:1393-1400.
32. Zhu N, Yu C, Guo Y, Bian Z, Han Y, Yang L, et al; China Kadoorie Biobank Collaborative Group. Adherence to a healthy lifestyle and all-cause and cause-specific mortality in Chinese adults: a 10-year prospective study of 0.5 million people. *Int J Behav Nutr Phys*

- 1
2
3
4 *Act* 2019;16:98.
5
6
7 33. Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J, et al. Epidemiological transition of stroke
8
9 in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project.
10
11 *Stroke* 2008;39:1668-74.
12
13
14 34. Wu Z, Yao C, Zhao D, Wu G, Wang W, Liu J, et al. Sino-MONICA Project: a collaborative
15
16 study on trends and determinants in cardiovascular diseases in China, part I: morbidity and
17
18 mortality monitoring. *Circulation* 2001;103:462-8.
19
20
21
22 35. Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, Incidence, and Mortality
23
24 of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults.
25
26
27 *Circulation* 2017;135:759-771.
28
29
30 36. Brandes A, Smit MD, Nguyen BO, Rienstra M, Van Gelder IC. Risk factor management
31
32 in atrial fibrillation. *Arrhythm Electrophysiol Rev* 2018;7:118-27.
33
34
35 37. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ. Validation of
36
37 clinical classification schemes for predicting stroke: results from the national registry of
38
39 atrial fibrillation. *JAMA* 2001;285:2864-2870.
40
41
42
43 38. Tohgi H, Tajima T, Konno T, Towada S, Kamata A, Yamazaki M. The risk of cerebral
44
45 infarction in non-valvular atrial fibrillation: effects of age, hypertension and
46
47 antihypertensive treatment. *Eur Neurol* 1991;31:126-130.
48
49
50 39. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for
51
52 stroke: the Framingham study. *Stroke* 1991;22:983-988.
53
54
55
56 40. Tang X, Hu Y, Chen D, Zhan S, Zhang Z, Dou H. The Fangshan/Family-based Ischemic
57
58 Stroke Study In China (FISSIC) protocol. *BMC Med Genet* 2007;8:60.
59
60

Supplementary Table 1 Multivariable hazard ratios (HRs) of all-cause, coronary heart disease, and stroke mortality according to baseline history of hypertension

Cause of mortality	N	Deaths	Adjusted HR (95% CI)	<i>P</i>
All-cause				
Baseline hypertension status				
No	5118	358	Reference	
Yes	2196	251	1.18 (0.99 to 1.40)	0.06
Coronary heart disease				
Baseline hypertension status				
No	5118	59	Reference	
Yes	2196	54	1.40 (0.95 to 2.07)	0.09
Stroke				
Baseline hypertension status				
No	5118	76	Reference	
Yes	2196	72	1.58 (1.12 to 2.22)	0.009

HR: hazard ratio; CI: confidence interval

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	<p>(a) Page 1, page 2, and page 3. The study was a prospective cohort study, which was conducted to explore the association between blood pressure and cardiovascular diseases mortality.</p> <p>The title was: The association between blood pressure levels and cardiovascular deaths: a 20-year follow-up study in rural China.</p> <p>(b) Page 2 and page 3. The abstract gave a brief introduction of the objectives, methods, results, and conclusions of the study.</p>
Introduction		
Background/rationale	2	Page 5 and page 6. In the introduction section, we demonstrated that the optimal blood pressure, particularly for systolic blood pressure (SBP) treatment target is unclear worldwide. The 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults recommended 130/80 mmHg as blood pressure target goals. However, the generalizability of SPRINT findings to populations at large with hypertension remains controversial.
Objectives	3	Page 6. We aimed to assess the relative risk of CVDs mortality associated with different stages of hypertension according to 2017 ACC/AHA using a 20-year follow-up study in China, to further evaluate the generalizability of SPRINT findings and explore the target blood pressure levels among Chinese populations.
Methods		
Study design	4	Page 6. As stated it in the Methods section, our study was a prospective cohort study.
Setting	5	Page 6. The study was a community-based follow-up study for the prevention and treatment of hypertension, which is being conducted in Fangshan District, Beijing, China.
Participants	6	Page 6 and page 7. As described in the Methods section about the participants, from January 1997 through June 1999, 8,189 participants aged 35 to 97 years were enrolled. Informed consent was obtained from all participants. In addition, the study was approved by the Institutional Review Board of Peking University Health Science Center.
Variables	7	<p>Page 7.</p> <p>The primary outcome variable was death from CVDs. The information of death was continuously obtained from the Death Surveillance System in the Center for Disease Prevention and Control in Fangshan District. Date of death was ascertained from the record in the system. We determined survival times from the date participants investigated in the baseline survey through December 31, 2017. Participants who were alive at the end of this period contributed with censored observations to the survival analyses of time to death. The causes of death were coded using the International Classification of Diseases, Ninth Revision (ICD-9) codes from 1997 to 2001, and International Classification of Diseases, Tenth Revision (ICD-10) codes from 2002-2017.</p>
Data sources/ measurement	8*	The primary exposure variables for these analyses included age at the enrollment and the blood pressure level at baseline. Data on sociodemographic characteristics,

lifestyles, and medical history of the participants were collected through questionnaire interview by trained staff members.

Participants were defined as never smokers, former smokers, and current smokers. Information on alcohol consumption was obtained through asking the participants to describe their drinking status: never, light (less than 2 drinks a day), or heavy (≥ 2 drinks a day). Further, the salt intake of the participants was assessed according to the question of what kind of taste they liked (salty taste, moderate, or light taste).

Physical measurements included height, weight, and blood pressure. Blood pressure levels were measured 3 times using a mercury sphygmomanometer by trained investigators. The mean of the 3 recorded measurements were included in the analysis. Hypertension was defined as SBP ≥ 140 mm Hg, systolic blood pressure (DBP) ≥ 90 mm Hg, self-reported antihypertensive medication in the past 2 weeks, or self-reported history of hypertension.

Bias	9	Page 8 and page 9. Potential bias may exist despite careful adjustment for potential confounders in the analysis.
Study size	10	Page 6 and page 7. A total of 7,314 participants (3,346 males and 3,968 females) were included in the analysis.
Quantitative variables	11	Page 9. Age and BMI were handled as quantitative variables in the models.
Statistical methods	12	(a) Page 8 and page 9. Student's t-test and Chi-square test were used to test the differences between different baseline hypertensive history groups for continuous variables and categorical variables, respectively. Person-years for each participant were calculated as the duration from the survey date at baseline through death date or date of lost to follow-up, whichever came first. The Cox proportional hazards regression model for CVDs death included baseline blood pressure level, age, sex, education level, body mass index, smoking status, alcohol use, dietary salt intake, antihypertensive medications, and family history of hypertension. Participants were classified as two groups according to baseline hypertensive status, and non-hypertension ($<140/90$ mmHg) was treated as reference. (b) Page 9. To test for possible interactions between age and hypertension, we categorized age with cutoffs of 60 years and hypertension as binary variables, and setting variable cross-product terms of hypertension (yes/no) with age (<60 and ≥ 60 years) in the model. Reference groups were SBP/DBP of less than 140/90 mm Hg and age of less than 60 years. We also performed a subgroup analysis according to baseline blood pressure levels (SBP/DBP: $<120/<80$, 120 to 129/ <80 , 130 to 139/80 to 89, 140 to 159/90 to 99, and $\geq 160/\geq 100$ mm Hg), where SBP/DBP of $<120/<80$ was treated as the reference group. (c) There was no missing data in the analysis since standard quality control criteria were adopted in our study. (d) Not applicable (e) We did not conduct any sensitivity analyses

Continued

on

next

page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Page 6 and page 7. Our study only had one stage, and all 7,314 participants were included in the analysis. (b) Not applicable (c) Not applicable
Descriptive data	14*	(a) Page 9 and page 10. Of the 7,314 participants (aged 50.65±11.8 years), the prevalence of hypertension was 30.02%. The proportion of people aged 60 years and above was higher in hypertensive patients (36.75%) when compared with non-hypertensive participants (19.05%, P<0.001). In addition, hypertensive patients were less educated than non-hypertensive participants (P<0.001). Moreover, there were more participants with tobacco smoking (49.27% vs. 44.92%) and alcohol consumption (31.74% vs. 30.15%) among hypertensive patients when compared with non-hypertensive participants. Furthermore, the percentage of obesity was higher among hypertensive patients when compared with non-hypertensive participants (P<0.001). (b) Not applicable
Outcome data	15*	Page 11. During the median follow-up of 20 years, we identified 350 deaths from CVDs (148 stroke, 113 coronary heart disease, and 89 other CVDs).
Main results	16	(a) Page 11 and page 12. We detected statistically significant association between hypertension and the risk of mortality from CVDs (HR=1.35; 95% CI, 1.08 to 1.69). In the subgroup analysis based on baseline age, we found that, for people aged 35-59 years, hypertensive patients had a higher risk of mortality from CVDs when compared to those without hypertension (HR=2.49; 95% CI, 1.77 to 3.50). (b) Page 11 and page 12. There was no significant association between hypertension and the risk of mortality due to CVDs among people aged 60 years and over (P>0.05). Thus, age may significantly modify the association between hypertension and risk of mortality from CVDs (P for interaction<0.001). (c) Not applicable
Other analyses	17	Page 12 and page 13. Hypertensive patients with SBP/DBP of 140-159/90-99 and ≥160/100 mm Hg were more likely to die of CVDs (HR=1.44; 95% CI, 1.02 to 2.03; HR=1.74; 95% CI, 1.22 to 2.48) when compared with participants with SBP/DBP of <120/80 mm Hg. However, we failed to detect significant associations between SBP/DBP of 130-139/80-89 mm Hg (HR=1.18; 95% CI, 0.85 to 1.64, P=0.32) and 120-129/<80 mm Hg (HR=1.38; 95% CI, 0.93 to 2.05, P=0.11) and the risk of mortality from CVDs, respectively. Further, among participants aged<60 years at baseline, similar trend was observed between hypertension and the risk of mortality due to CVDs, where HR was 2.32 (P<0.001) for SBP/DBP of 140-159/90-99 mm Hg and 3.25 (P<0.001) for ≥160/100 mm Hg, respectively. However, there was no significant association between hypertension and the risk of mortality from CVDs with different baseline blood pressure levels for those aged≥60 years (P for interaction<0.001).

Discussion

Key results	18	Page 14, page 15, and page 16. The present 20-year prospective study filled the gaps for implying the generalizability of the 2017 ACC/AHA Hypertension Guideline to Chinese populations. The results showed there was no significant association between stage 1 hypertension defined by the 2017 ACC/AHA and CVDs mortality when compared with SBP/DBP of <120/80. In addition, we detected high blood pressure was associated with higher mortality from CVDs among people aged 35-59 years rather than those aged 60 years and over. The findings may contribute to the optimal management of hypertension to address the
-------------	----	---

growing burden of CVDs morbidity and mortality in China, suggesting a large implication both to clinicians and public health practitioners.

Limitations	19	Page 17 and page 18. Nevertheless, the study has several limitations. Firstly, we cannot exclude the influence of some potential confounding factors despite we conducted the analysis with careful adjustment. In particular, the definition of smoking, alcohol consumption, salt intake, and the use of antihypertensive drugs was relative simple due to limited information in the baseline questionnaire. Secondly, hypertension was defined by SBP/DBP at baseline while we failed to acquire blood pressure measurements during follow-up, which may underestimate the strength of the associations we observed. Next, we had insufficient sample size to explore whether the effects of hypertension on CVDs mortality differ by baseline comorbidities including diabetes or chronic kidney disease. In addition, information of death was obtained from the Death Surveillance System, the participants lost to follow-up were hard to detect and may cause potential bias. Therefore, further studies with a larger sample size are needed to validate the results in the study. More importantly, our study only included participants in rural China, which might limit the generalizability of the results to other populations with different socioeconomic status, environmental exposures, or genetic background.
Interpretation	20	Page 14, page 15, and page 16. From an objective perspective, we discussed the results from the aspects recommended in the STROBE Checklist.
Generalisability	21	Page 18. The current study revealed hypertension of $\geq 140/90$ mm Hg was an important risk factor of CVDs mortality, especially among people aged 35 to 59 years. However, stage 1 hypertension under the definition of 2017 ACC/AHA was not associated with increased risk of CVDs mortality. This study indicated that whether adopting the new hypertension definition needs further consideration in rural China.

Other information

Funding 22 Page 18. All sources of funding were described in the Acknowledgement section.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.